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Human knowledge is insufficient and the 
conclusions of science cannot indicate by 
themselves the path towards integral human 
development. There is always a need to push 
further ahead: this is what is required by 
charity in truth. Going beyond, however, never 
means prescinding from the conclusions of 
reason, not contradicting its results. 
Intelligence and love are not in separate 
compartments: love is rich in intelligence and 
intelligence is full of love. 
Benedict XVI 
Charity in Truth 
Encyclical Letter, 2009 
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“There are many success stories in the history of Parkinson’s disease. Our under-
standing of the condition has greatly evolved since it was first identified as the shaking 
palsy 193 years ago. We have made progress in defining the underlying pathology and 
tracking disease progression, and better treatments improve patient quality of life. Yet, 
a cure remains elusive. Unlike other neurodegenerative conditions, Parkinson’s disease 
has had a successful symptomatic drug available for more than 40 years. Levodopa is 
the mainstay of Parkinson’s disease treatment, but although its pharmacology and 
delivery have been altered and improved over the years, it is still far from ideal. And 
herein lies perhaps the ultimate frustration: despite several decades of searching, 
levodopa is still the best there is. That is not the only challenge. Can we detect the 
disease before major, perhaps irreversible degeneration has occurred? What will it take 
to replicate this disease in animal models to enhance our understanding of it and aid 
development of novel treatments? And how can new, potentially disease-modifying 
therapies be appropriately tested in patients?” 
 Michelle Grayson, Associate Editor, Nature Outlooks, August 2010 
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INTRODUCTION 
Neuroinflammation in neurodegeneration 
Inflammatory responses have now been associated with many chronic 
neurodegenerative conditions (e.g., Multiple sclerosis, Alzheimer disease, Amyotrophic 
lateral sclerosis and Parkinson’s disease). Neuroinflammation is a process not easy to 
define: traditionally, it involves the succession of complex and integrated cell processes, 
the integrity of which is mediated by the synthesis/release of pro-inflammatory 
mediators, such as cytokines and chemokines. Inflammatory responses are usually 
localized and characterized by an active communication between immune, vascular, and 
parenchymal cells. Outside of the CNS, cell types recruited in inflammation are 
monocytes, neutrophils and macrophages. These cells elaborate integrated cascades 
producing reactive oxygen species at sites of infection or injury. Resident populations of 
tissue macrophages play key roles as sentinels of infection and injury, but are also 
increasingly recognized as having an influence on normal tissue homeostasis. 
In the brain all neural cells, such microglia, astrocytes, neurons and 
oligodendrocytes participate to the inflammatory response with different roles and 
timing. Additionally, dysfunction of the blood-brain barrier (BBB) combined with 
infiltration of peripheral immune cells could be important players. Similarly to other 
districts, in the CNS the microglia exhibit a dormant phenotype in healthy condition and 
may play important roles in maintenance of tissue homeostasis in processes like 
neuropathic pain, stress, autonomic and immune response through the communication 
with astrocytes and neurons, analogously to the homeostatic role described for the 
“alternatively activated” macrophages in other tissues (Milligan, 2009; Streit, 2005; 
Verkhratsky, 2007). Neuro-inflammation is normally considered a protective 
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mechanism that circumscribes the damaged areas in the brain, destroys affected cells 
and modify the extracellular matrix (Streit, 2002; Correale and Villa, 2004; Bauer, 
2007; Sofroniew, 2001). Without local and well balanced inflammatory responses, brain 
tissue would be more vulnerable to acute trauma and microbial, viral and prion 
infections.  The firs and dominant reaction to all types of CNS injuries consists in the 
activation of resident immune cells, often referred to as gliosis, at the sites of damage 
(Kreutzberg, 1996; O’Callaghan, 2005; Glass, 2010). Morphologically, gliosis consists 
in macroscopic changes in glial cells phenotypes, mainly consistent in the activation and 
transformation of microglial cells into phagocitic cells, and, to lesser extent, in reactive 
astrocytosis (Narassimahan, 2005; Kattenmann, 2006; Kattenmann, 2007; Napoli and 
Neumann, 2009; Sofroniew, 2010). Mediators of this gliosis already identified are 
cytokines, chemokines and reactive oxidant species. Microglia and astroglia per se are 
also a source of inflammatory mediators and reactive oxidant generators, which can 
perpetuate the inflammatory reaction in an autocrine manner, given rise to the so called 
“dark-side” of glia (Miller, 2005).  
All glial cells normally switch to what can be considered an “activated” 
phenotype in response to a pathogen invasion or tissue damage, thereby promoting an 
inflammatory response which serves to further engage the immune system and initiate 
tissue repair. In most cases, this response is self-limiting, resolving once infection has 
been eradicated, or the tissue damage has been repaired. However, sustained 
inflammation, which results in tissue pathology, implies the persistence of an 
inflammatory stimulus or a failure of the normal resolution mechanisms. A persistent 
stimulus could be determined by environmental or endogenous factors (e.g. protein 
aggregates) that may be perceived by the resident glia like a “danger signal”. In these 
cases, the normal restoring mechanism is bypassed, leaving the place to a chronic 
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inflammatory process. Chronic neuro-inflammation differs from the acute inflammation 
mainly because it is below the threshold of pain perception. This condition makes 
possible that the inflammatory state may continue for years, causing a persistent insult 
to the brain and producing neurotoxic factors that impair the pathological state, 
ultimately showing clinical manifestations. The molecular mechanisms and the internal 
and external factors that modulate the dynamic aspects of the acute and chronic neuro-
inflammations remain unclear. Furthermore, it is poorly understood to what extent 
neuroinflammation is beneficial for the injured or infected brain, and how may 
contributes to secondary brain injuries and progressive neuronal loss.   
Mechanisms of neuroinflammation 
Inflammatory responses to infectious agents are typically initiated by pattern 
recognition receptors, which bind to so-called pathogen-associated molecular patterns 
(stranger signals). One class of pattern recognition receptor is exemplified by the Toll-
like receptors (TLRs), which recognize a diverse set of pathogen-associated molecules 
that are not present in the host. For example, TLR4 recognizes the lipopolysaccharide 
(LPS) associated with gram-negative bacteria, whereas TLR3 recognizes viral double-
stranded RNA. These receptors are expressed on many cell types, but are highly 
expressed on cells that play central roles in innate immune responses, including 
macrophages and microglia. Pattern recognition receptors have more recently been 
found to also be capable of responding to endogenously derived molecules, such as 
components released from necrotic cells (danger signals) and by molecules that may be 
formed as a consequence of pathogenic mechanisms. Roles of TLR2 and TLR4 have 
recently been established in the pathogenesis of several chronic inflammatory diseases 
by using animal models, and specific TLR4 polymorphisms have been demonstrated to 
be associated with several human age-related diseases, including atherosclerosis, type 2 
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diabetes, and rheumatoid arthritis, raising the question of whether these receptors also 
contribute to inflammatory programs associated with neurodegenerative disease 
(Balistreri, 2009). In addition to pattern recognition receptors, purinergic receptors are 
expressed on microglia and astrocytes and respond to ATP released from cells 
following death, traumatic injury, or ischemia (Di Virgilio, 2009). Microglia and 
astrocytes express a number of so-called “scavenger receptors” that have been 
demonstrated to be involved in the uptake of a number of substrates, including oxidized 
proteins, lipids and apoptotic cells, and that may also contribute to cell signaling 
(Husemann, 2002). 
Normally, to bring about an effective immune response, the initial detection of a 
microbial pathogen must be amplified to recruit additional cells to sites of infection, 
induce antimicrobial activities and initiate the development of an adaptive immunity. 
Therefore important subsets of highly induced genes include: cytokines which amplify 
the program of inflammation, and chemokines (e.g., Monocyte chemotactic protein-1, 
MCP-1), which recruit additional immune cells. Generally, the onset of inflammation is 
often characterized by the release of pro-inflammatory cytokines, such as (Tumor 
necrosis factor, TNF), interleukin (IL)-1 and adhesion molecules. Many of these 
secreted factors influence the system in both autocrine and paracrine fashions. In 
addition to the activation of local glia and the recruitment of blood-borne leukocytes, 
local synthesis of inflammatory-related cytokines elicits a wide range of effects 
including: cell adhesion, migration, survival, differentiation, replication, secretory 
function and death. In the same cell, a cytokine can exert opposite effects, inducing 
death, survival, or proliferation depending upon the functional context in which it acts. 
For IL-1 and TNFα, these effects are mediated primarily by IL-1 type I receptor (IL-
1R1) and TNFR1 (p55) or 2 (p75), respectively. While a pathophysiological role for IL-
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1 as part of inflammatory processes in the brain has been established, is still unclear 
how exactly the signaling process contributes to neuronal death and/or protection. 
However, experimental data support its role as a key mediator of inflammation and 
neuronal death in acute brain injuries, such as stroke and trauma (Allan, 2005).  
The multiple functions of microglia related to an innate immune response are associated 
with TNFα signaling and its regulation of both inflammation and apoptosis. TNFα is a 
multipotent, inflammatory cytokine that can induce apoptosis via activation of receptors 
containing a homologous cytoplasmic sequence, which identify an intracellular death 
domain. These include TNFR1 and CD95 (APO-1/Fas) and their corresponding death 
ligands, TNFα and the structurally related type II transmembrane protein, FasL. The 
release of TNFα and FasL shedding by microglia are implicated in neurotoxicity (Badie, 
2000; Taylor, 2005).  
Membrane receptors implicated in apoptotic neuronal death, involve 
downstream intracellular death-signaling complexes, such as AP-1, NF-κB, and 
caspases. TNFR1 activation, for example may provide a molecular mechanism for the 
rapid apoptosis of injured or sick neurons through a caspase 3-mediated pathway (Yang, 
2002).  
The tissue distribution of these receptors and the differentiation state of the 
target cells influence the cellular response to cytokines. Neither TNFα nor IL-1β have 
been demonstrated to cause neuronal death in healthy brain tissue or normal neurons, 
(Gendelman, 1999), and a normal cellular architecture is maintained in mice deficient in 
pro-inflammatory cytokines or in their receptors. However the cascades in which these 
cytokines take part support the hypothesis that localized pro-inflammatory cytokine 
activation could initiate neuronal death in altered tissue. In fact, increases in TNFα and 
IL-1β levels and activation have been observed prior to neuronal death (Matusevicius, 
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1996; Lefebvre d'Hellencourt, 2005; Harry, 2008; Kaushal, 2008; Harry, 2008). In 
addition, in the neuro-inflammatory cascades, genes that encode proteins with 
antimicrobial activities (e.g., Inducible nitric oxide synthases, iNOS) and/or that 
influence substrate metabolism, protein synthesis, cell motility, phagocytosis, apoptosis, 
and antigen presentation are induced. The generation of reactive oxygen species (ROS), 
e.g., through the nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase 
system, is an important antimicrobial mechanism, but also exemplifies a system that can 
result in collateral damages to the tissue, e.g., to the parenchymal cells in the brain.  
ROS are multi-potent, diffusible molecules capable of carrying out signal transduction 
processes in response to extracellular stimuli and their role in enhancing gliosis has 
been proposed by studies showing its inhibition following antioxidant treatment. 
Recently, NADPH oxidase was identified as the ROS-producing molecule in astrocytes: 
here cytokine stimulation leads to a rapid NADPH oxidase activation followed by the 
expression of pro-inflammatory products, such as iNOS (Pawate, 2004). The generation 
of ROS and the induction of iNOS enhance NO production from both glial and 
endothelial cells. NO is both a vasorelaxant, and neurotransmitter that at high 
concentrations, forms peroxynitrite. Moreover by nitrosylation of cell signaling 
messengers NO may act as an immune regulator (Guix, 2005). ROS signaling has been 
considered as a unifying factor underlying multiple forms of neuro-inflammation and 
microglia responses. However, many of these studies have been conducted in vitro and 
raise the question of how to transpose these mechanisms to an in vivo situation.  
CNS is an immunologically privileged site and circulating immune cells 
normally do not have access to it in the absence of inflammation or injury. As dendritic 
cells, with specialized antigen-presenting capabilities, in the peripheral immune system, 
microglia appear to be the major initial sensors of danger or stranger signals recognized 
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by TLR4, and they secrete inflammatory mediators such as TNF-α and IL-1β that can 
act on astrocytes to induce secondary inflammatory responses (Saijo, 2009). However, 
not only CNS resident cells are involved in neuro-inflammation. A somehow indirect 
mechanism of communication between the systemic and central immune systems exists. 
Cytokines circulating within the bloodstream can signal via binding to receptors on 
neurovascular endothelial cells. Pro-inflammatory cytokines released upon immune 
challenge can also activate vagal afferent signaling and subsequent direct, or indirect, 
activation of vagal efferents. This has been proposed as a demonstration that the sensory 
vagal afferents, together with the regulatory vagal efferents, form an inflammatory 
reflex that continually monitors and modulates the inflammatory status in the periphery 
(Tracey, 2002).  
Peripheral lymphocytes (T and B cells) that infiltrate the brain have been shown 
to participate in the local response to acute and chronic CNS injury, in addition to 
resident microglia and infiltrating macrophages. T-cells participate in different ways. 
The exacerbated immune response may be deleterious for the CNS as occurs in multiple 
sclerosois (MS). T-cells are primed to react to specific myelin antigens in MS, but could 
also promote neuronal survival in animal models of nerve crush and other physical 
injuries (Schwartz, 1999) and have been shown to protect hippocampal neurons against 
chemical exposure to the organometal trimethyltin (Kurkowska-Jastrzebska, 2007). 
There are also new evidences that cytokines produced during infection/inflammation 
activate the adaptive central nervous system responses, including acute stress responses 
mediated by the hypothalamo-pituytary-adrenal axis (Serrats, 2010). Overall, these 
studies demonstrate that CNS responses previously considered to be the result of CNS 
tissue specific cells may involve contributions from multiple cell types, the actions of 
which are significantly influenced by the systemic state of the organism. 
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Finally, the variety of factors secreted during neuroinflammation could also 
affect another group of cells resident of the CNS, modifying their functions: the 
oligodendrocytes (OLs). OLs are mature glial cells that myelinate axons in the brain and 
spinal cord. As such, they are crucial for the appropriate function and efficient neuronal 
signaling. OLs and their precursors are very vulnerable to conditions common to CNS 
injury and diseases, such as inflammation, oxidative stress and elevated glutamate levels 
which leads to excitotoxicity. Thus, these cells become dysfunctional or die in several 
pathologies including Alzheimer’s disease (AD), spinal cord injury and ischemia. In the 
adult brain, the consequence of their death, or of any other defect in the differentiation 
of the precursors cells (OPCs) into myelin sheath producing mature OLs, is an 
inadequate re-myelination in case of injuries. The failure of remyelination has profound 
consequences for the function and preservation of axons, the progressive and 
irreversible loss of which accounts for the progressive nature of the above mentioned 
neurodegenerative diseases. In MS, for example, neuro-inflammation seems to be 
crucial in determining the severity of the progression of the disease.  Although many 
studies in the past few years have concentrated on putative inhibitory signals, in their 
attempt to account for the failure of OPCs to undergo complete differentiation in 
demyelinated MS plaques, an alternative explanation is that these lesions fail to 
remyelinate because of a deficiency in the signals that induce differentiation. This 
hypothesis, based on the absence of promoting factors, is difficult to prove, but it is 
consistent with a model of remyelination, in which the acute inflammatory events have 
a key role in activating precursors and in creating an environment that is conducive to 
remyelination. MS lesions are rarely devoid of any inflammatory activity; however, 
chronic lesions are relatively non-inflammatory compared with acute lesions and 
constitute a less active environment in which OPCs differentiation might become 
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quiescent. The difference between inflammatory and non-inflammatory environments, 
which models chronic lesions in a promoting regenerative behavior, has been 
demonstrated in two recent studies based on the myelinating potential of transplanted 
OPCs (Setzu, 2006; Foote & Blakemore, 2005). Chronic lesions usually contain 
scarring astrocytes, which are hypertrophied and nonreactive, in contrast to the reactive 
astrocytes associated with acute lesions and that support remyelination through the 
production of growth factors (Redwine & Armstrong, 1998; Albrecht, 2003; Williams, 
2007). Although these non reactive astrocytes are likely to be the consequence and not 
the cause of remyelination failure, their presence might not be helpful when attempting 
to promote remyelination in chronic lesions.  
In this introductory section, only a few of the inducers, sensors, transducers and 
effectors of neuro-inflammation that could contribute to neuronal dysfunction or death 
have been mentioned. Although the inducers of inflammation may be generated in a 
disease-specific manner, there is a clear evidence for a remarkable convergence of the 
mechanisms responsible for signaling, transducting and amplifying inflammatory 
processes, which result in the production of neurotoxic mediators. Over more, a major 
unresolved question is whether inhibition of these responses will be a safe and effective 
strategy for reversing or slowing the progression of neurodegenerative diseases. To 
effectively respond to this question, it would be necessary to learn more about how 
neuro-inflammation is induced in the CNS and why it may contribute to different brain 
pathologies. 
 
Neuroinflammation in Parkinson’s disease and experimental parkinsonism 
Increasing evidence suggests that some neurodegenerative diseases, as Parkinson’s 
disease (PD), are influenced by marked inflammatory phenomena (Appel, 2009; Hirsch 
and Hunot, 2009; McAllister and van de Water, 2009). PD is the second most common 
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neurodegenerative disease after Alzheimer’s disease (AD) and represents the most 
common movement disorder. Currently, about 2% of the population over the age of 60 
is affected. Prominent clinical features are motor symptoms (bradykinesia, tremor, 
rigidity, and postural instability) and non-motor-related symptoms (anosmia, autonomic 
dysfunction, depression, cognitive deficits and sleep disorders). Major 
neuropathological hallmarks of the disease are the loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) in the midbrain, as well as in other brain regions 
(Fig. 1A, B), and the formation of intracellular proteinaceous inclusions, mainly 
containing aggregates of α-synuclein, preferentially localized within affected neurons 
perikaryon and processes, called Lewy bodies and Lewy neurites, respectively (Braak, 
2003). In fact, as AD, PD can be defined as a “proteinopathy”, characterized by the 
accumulation and aggregation of misfolded proteins. 
 
 
A 
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Fig.1 (A) Striatal dopamine innervation assessed by 18F-dopa positron emission tomography. (a) Mean control 
values for eight control subjects shows high uptake (highest value in white) in the striatum. (b) Subject with 
Parkinson’s disease (right) featuring slowness and rigidity on the right limbs but minimal signs on the left limbs. 
Uptake is markedly reduced (70% below normal) in the left posterior putamen and reduced to a minor extent in the 
anterior putamen and caudate of the left hemisphere. (c) SPM2-based analysis (yellow represents the largest 
statistical difference and red the smallest one), showing the difference in uptake between a and b to highlight the 
caudorostral pattern of denervation. The statistical map is rendered over the MRI for anatomical localization. 
(B) Distribution of Lewy bodies in Parkinson’s disease. Diagrammatic representation of pathological data from 
longitudinally studied cases showing the severity of midbrain dopamine cell loss and Lewy body infiltration over 
time in an average individual who develops symptoms around 55 years of age versus one who develops symptoms 
after the age of 70. The severity of dopamine cell loss is related to the duration of symptoms, with those with longer 
durations having greater cell loss (represented as progressively darker color). The infiltration of Lewy bodies appears 
more marked in late-onset disease, and in many instances, individuals with late-onset disease have additional age 
relate pathologies (represented as cortical plaques). Dementia, as indicated in the lower bar, occurs earlier in the 
disease in older onset individuals, consistent with the greater pathology observed. (Obeso JA et al., 2010) 
 
The etiology of the most common forms of PD remains poorly understood. 
Originally thought to be a disease characterized by loss of one neuronal type, PD is now 
recognized to have a prominent inflammatory component (Block and Hong, 2007; 
McGeer and McGeer, 2008; Nagatsu and Sawada, 2005). Post-mortem analysis of the 
most evident degenerating region of PD patients brains, the SNpc, revealed an increased 
number of activated microglial cells expressing human leukocyte antigen (HLA)-DR 
and CD11b (McGeer, 1988; Gerhard, 2006) and reactive astrocytes (Forno, 1992; 
Damier, 1993; Braak, 2007), indicating events of active nerve degeneration. By positron 
B 
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emission tomography of PD patients it has been shown also a marked increase in the 
expression by glial cells of peripheral benzodiazepine receptor, reflecting the evident 
gliosis. In addition, increased levels of cytokines in brain and blood have been reported 
(Nagatsu and Sawada, 2005). The biochemical and histological hallmarks of the 
inflammatory activation, such as increased levels of cytokines and glial activation may 
be intimately related with new processes of neuronal degeneration (Bjorkqvist, 2009; 
Hirsch and Hunot, 2009). For example, increased levels of pro-inflammatory cytokines, 
such as TNF-α (Mogi, 1994b; Reale, 2009; Scalzo, 2009) and interferon γ (IFN-γ) 
(Mount, 2007; Reale, 2009) have been shown in the blood serum of PD patients and 
post-mortem analysis of PD-affected human brains show a similar increase of these 
cytokines in the nigrostriatal system (Mogi, 1994a; Mogi, 1994b). The cause of this 
cytokine-mediated inflammatory reaction observed in the brain, as well as outside the 
central nervous system (CNS), is poorly understood. It may be potentially mediated by 
the activation of glial cells that are thought to produce and release these cytokines in the 
CNS during dopaminergic degeneration (Hirsch, 1998; Nagatsu and Sawada, 2007). 
Although these inflammatory components are not specific for PD, they might provide 
useful biomarkers for monitoring the progression of the disease.  
As is the case for AD, rare mutations in a number of genes cause familial forms 
of PD and provide insights into general pathogenic mechanisms (Gasser, 2009). Among 
these, are mutations in α-synuclein, parkin 1 and 4 (PARK1 and PARK4) and DJ-1 
(PARK7). Alpha-synuclein is a 140 amino acid protein that is physiologically present in 
the presynaptic terminals of neurons. It plays a major role in PD neuropathology: α-
synuclein aggregates in PD and becomes the major fibrillar protein included in Lewy 
bodies in both sporadic and inherited forms of PD. Moreover, point mutations (A53T, 
A30P, E46K) and gene multiplications of human wild-type α-synuclein are related to 
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rare familial autosomal-dominant forms of early-onset PD. In PD, the aggregation of α- 
synuclein from monomers, via oligomeric intermediates, into fibrilary aggregates is 
considered the disease-causing toxic mechanism. Recent reports indicate that the 
accumulation of α-synuclein can result in the formation of intermediate state oligomers, 
which lead to neuronal cell death (Danzer, 2007). One line of research proposes that 
neuronal death itself, with the consequent release of protein aggregates, induces 
activation of microglia. Additional activation of microglia may be due to the release of 
aggregated proteins from neurons into the extracellular space (Roodveldt, 2008). This 
finding is interesting, as the α-synuclein-related neuropathological alterations in 
sporadic PD and in most of the forms of familial PD were initially thought to be 
intracellular. Recent data challenge this model and indicate the importance of 
extracellular α-synuclein aggregates in PD (Lee, 2008). Extracellular α-synuclein is 
probably phagocytosed by microglia (Zhang, 2005), and aggregated, nitrated, and 
oxidized forms of α-synuclein have been found to induce microglial activation 
(Reynolds, 2008; Zhang, 2005). Sensing mechanisms for α-synuclein aggregates are 
similar to those for viruses and toxins, as extracellular α-synuclein is suggested to be 
sensed and internalized by cell surface gangliosides in BV-2 cells (a microglia cell line) 
in vitro. The internalization of α-synuclein by microglia is followed by activation of the 
NADPH oxidase, production of ROS and release of proinflammatory cytokines (Zhan, 
2005). However, it has recently been reported that microglial immunity stimulated by 
nitrated α-synuclein is regulated by CD4+ T regulatory (Treg) cells. Treg cells may alter 
the proteome of microglia in response to nitrated α-synuclein, thereby protecting 
dopaminergic neurons (Benner, 2008; Reynolds, 2008). A characteristic of 
dopaminergic neurons of the SN is an increase of the intracellular oxidative processes 
related to the synthesis of dopamine (Thomas, 2008), making them particularly 
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vulnerable to oxidative stress. In addition, high rates of catecholamine metabolism drive 
the production of neuromelanin, and high amounts of neuromelanin are suspected to 
increase the vulnerability of dopaminergic midbrain neurons to oxidative stress 
(Kastner; Herrero, 1993a-b).  In fact, a direct effect of neuromelanin on the activation of 
microglia through the activation of the NF-κB pathway has been shown in cultures of 
rodent microglial cells (Wilms, 2003). 
 As the vast majority of PD cases are sporadic, environmental factors that interact 
with common, but less penetrant, susceptibility genes are likely to influence the onset of 
most cases of sporadic PD (Tansey, 2007). PD-causing toxins, like insecticide or drug 
derivate, are known to induce neuronal degeneration associated with reactive 
microgliosis, which exacerbates neurotoxicity.  
The role of bacterial or viral infection as an initiating factor in human PD is 
unclear, but intracranial infusion of the bacterial lipopolisaccaride (LPS) in rodents is 
used as an alternative model for microglia-induced loss dopaminergic neurons, 
evaluated by tyrosine hydroxylase (TH) immunolabeling (Castaño, 2002; Herrera, 
2000). LPS-induced inflammation can also synergize with mutations in α-synuclein and 
Parkin genes, which are associated to familial PD, to potentiate the loss of TH-positive 
neurons in animal models (Gao, 2008). Whether other neuronal populations are affected 
remains to be established. 
PD is unique among the neurodegenerative disorders, in that we understand a 
great deal about its circuitry and physiology, which are to a large extent caused by the 
loss of the dopaminergic neurons of the SNpc (Fig. 3). This knowledge has led to 
effective symptomatic treatment of the motor manifestations of the illness, initially with 
levodopa (l-DOPA) and then later with dopamine receptor agonists and deep brain 
stimulation (Obeso, 2010).  
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Fig. 2. Summary of the main connections of 
the “motor circuit” of the basal ganglia. In the 
normal state, the putamen receives afferents from 
the motor and somatosensory cortical areas and 
communicates with the GPi/SNr through a direct 
inhibitory pathway and though a multisynaptic 
(GPe, STN) indirect pathway. Dopamine is 
believed to modulate striatal activity, mainly by 
inhibiting the indirect and facilitating the direct 
pathways. In Parkinson’s disease (PD), dopamine 
deficiency leads to increased inhibitory activity 
from the putamen onto the GPe and disinhibition 
of the STN. In turns, STN hyperactivity by virtue 
of its glutamatergic action produces excessive 
excitation of the GPi/SNr neurons, which 
overinhibit the thalamocortical and brain stem 
motor centers. (Obeso JA et al., 2002) 
 
 
 
Yet, the efficacy of symptomatic therapies wanes after five to ten years, and patients 
develop increasing motor impairment, gait and postural difficulties, and cognitive 
dysfunction. The major goal of medicine is to develop disease-modifying treatments, 
therefore a better understanding of the disease pathophysiology, embodied in better 
animal models, is necessary. 
In order to be both a good model of human PD and a good test subject for new 
therapies, the ideal animal model should have a number of characteristic features: First, 
there should be a normal complement of dopaminergic neurons at birth, more than 50% 
of which are then selectively, gradually and measurably lost in adulthood; Second, the 
model should have motor deficits, including the cardinal symptoms of PD; Third, it 
should show the characteristic Lewy body neuropathology; Fourth, if the model is 
genetic, it should be based on a single mutation to allow robust propagation and 
facilitate crossing with enhancer, or suppressor, strains; Fifth, it should have a relatively 
a short disease time-course of a few months, allowing rapid and less costly screening of 
therapeutic agents. 
22 
 
Traditional animal models of PD are based on the use of toxins, which 
selectively accumulate in the SNpc neurons, causing cellular dysfunction and death. 6-
hydroxydopamine (6-OHDA) is one of such compounds that produce SN degeneration 
in mice, rats, cats and primates. The standard approach is to use 6-OHDA to create a 
unilateral lesion in the brain, which is followed by administration of amphetamine. This 
causes the animal to start rotating ‘away from’ the lesion. This rotary behavior can be 
reversed, for example by treatment with dopaminergic stem cells that restore normal 
circuitry (Marin, 2006; Jenner, 2008). 
The insecticide rotenone can also be used to create an animal model, as its 
administration specifically inhibits the complex I of the mitochondrial electron-transport 
chain. Betarbet and colleagues (Betarbet, 2007) produced a model of PD by infusing 
rats intravenously with rotenone. The rats developed progressive degeneration of 
nigrostriatal neurons, as well as cytoplasmic inclusions reminiscent of Lewy bodies. 
They also exhibited bradykinesia, postural instability and an unsteady gait, all of which 
improved after treatment with the dopamine agonist apomorphine. Other compounds 
that have been shown to produce selective degeneration of dopaminergic neurons 
include paraquat and trichloroethylene, both of which have been implicated in the 
causation of human Parkinson’s disease. However, there is substantial variability in all 
of these models, which limits their usefulness for therapeutic development. 
The best characterized toxin-based model of PD uses the MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine). Although MPTP-treated monkeys remain the gold 
standard for pre-clinical testing of new therapies, most of the studies geared toward 
unraveling the mechanisms underlying the dopaminergic neuronal death have been 
performed in mice using several different well validated regimens.  MPTP has become 
the most commonly used, for at least three reasons. First, MPTP is the only known 
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dopaminergic neurotoxin capable of causing a clinical picture in both humans and 
monkeys indistinguishable from PD (Langston, 1983). Second, although handling 
MPTP requires a series of precautions, its use is not otherwise technically challenging: 
it does not require any particular equipment such as stereotaxic frame, nor it requires 
surgery on live animals as for 6-hydroxidopamine or rotenone. Third, MPTP produces a 
reliable and reproducible lesion of nigro-striatal dopaminergic pathway after its 
systemic administration, which is often not the case for other documented toxins (Bove, 
2006).  The importance of this compound was discovered accidentally in 1982, when a 
group of young drug takers in California developed subacute onset of severe 
parkinsonism, caused by contamination of a synthetic opiate with MPTP. The post-
mortem study of human subjects accidentally intoxicated showed not only the 
characteristic dopaminergic degeneration already observed in sporadic PD, but also the 
same maintained glial reaction in the SNpc evidenced by activated microglia and 
reactive astrocytes, many years after the neurotoxin insult (Langston, 1999).  
The administration of MPTP was subsequently shown to model Parkinson’s 
disease in both mice and primates, by inhibiting part of the electron-transport chain in 
dopaminergic neurons of the SN. The metabolism of MPTP is a complex, multistep 
process (Tipton and Singer, 1993; Dauer and Przedborski, 2003) (Fig. 3). After 
systemic administration, the highly lipophilic MPTP rapidly crosses the blood-brain-
barrier. Once in brain, the pro-toxin MPTP is assumed by glial cells, possibly 
astrocytes, metabolized in 1-methyl-4-phenyl-2,3-dihydropyridinium by the monoamine 
oxidase B (MAO-B) and then (hypothetically by spontaneous oxidation) transform into 
1-methyl-4-phenylpyridinium (MPP+), which is the active toxic compound. Thereafter, 
MPP+ is released into the extracellular space. Since MPP+, unlike its precursor MPTP, is 
a polar molecule, it cannot freely enter cells, but depends on plasma membrane carriers 
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to gain access to neurons. In particular, MPP+ has a high affinity for the dopamine 
transporter localized on the plasma membrane of dopaminergic neurons, as well as for 
serotonin transporters (Javitch, 2000). Once inside dopaminergic neurons, MMP+ can be 
sequestered into synaptosomal vesicles (Liu Y, 1992), or concentrate within 
mitochondria (Ramsay, 1986), where MPP+ inhibits part of the electron-transport chain 
by specifically inhibiting the complex I. This results in the reduction in ATP synthesis 
and, more importantly, in the increased production of free radicals, which causes 
oxidative stress and activation of programmed cell death molecular pathways. 
 
 
 
Fig. 3. MPTP metabolism. MPTP is a pro-toxin that, due to its lipophilic nature, rapidly crosses the blood–brain 
barrier and is metabolized to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+) by the enzyme monoamine oxidase 
B (MAO-B) present in glial cells. Here, probably by spontaneous oxidation, it is converted in 1-methyl-4-
phenylpyridinium (MPP+), the active toxic compound. MPP+ is released in the extracellular space and taken up by 
the DA transporter present on the plasma membrane of the synaptic endings of DA neurons. Once inside DA neurons, 
MPP+ is concentrated by an active process within the mitochondria, where it impairs mitochondrial respiration by 
inhibiting complex I of the electron transport chain (Vila and Przedborski, 2003) 
 
MPTP toxicity in primates replicates all of the cardinal clinical signs of 
Parkinson’s disease. It has, therefore, proved to be useful for studying the striatal 
circuitry involved in Parkinson’s disease pathophysiology. MPTP causes loss of 
neurons located in the SNpc and in the locus coeruleus, which are particularly 
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vulnerable to the pathologic process in Parkinson’s disease, whereas other neurons, such 
as those of the dorsal motor nucleus of the vagus and of the nucleus basalis of Meynert, 
are spared. Acute administration of MPTP does not induce Lewy body formation, 
although chronic administration triggers the production of -synuclein inclusions.  
One of the most interesting aspects concerning the pathophysiology of MPTP-
induced parkinsonism in monkey is a prominent glial response, which lasts years after 
MPTP injections and establishment of a stable parkinsonism. This inflammatory 
reaction is confined to the SNpc and striatum (McGeer, 2003; Barcia, 2004) and is 
simultaneous to a persistent increase in TNF-α levels in the blood (Barcia, 2005). This 
evidence indicates that the glial cell reaction and inflammatory response persist over a 
period of at least 2 years in parkinsonian primates, even though new neurotoxic insults 
are apparently absent. This combines with observations on autopic human brain of drug 
addicted and PD patients (Langston, 1999; McGeer, 2004). The current hypothesis is 
that in PD as well as in MPTP-induced parkinsonism, the initial neuronal damage 
triggers glial activation and a neuroinflammatory response, which are able to perpetuate 
themselves, possibly contributing to progressive neuronal loss. To date, the mechanisms 
involved in the perpetuation of this glial cell activation in brain remain unclear. Pro-
inflammatory cytokines like TNF-α and IFN-γ are good candidates (Tedeschi, 1986; 
Dickson, 1993; Benveniste, 1994; Hanisch, 2002), although, it has not been clearly 
demonstrated whether microglia, or astroglia, produce and release these cytokines in 
vivo, or how this process may take place in parkinsonism. On the contrary, it is well 
known that TNF-α and IFN-γ are important cytokines involved in dopaminergic 
degeneration. In fact, blocking TNF-α activity protects against dopaminergic neuronal 
loss, and mice lacking the TNF-α receptor are protected against MPTP-induced 
degeneration (Sriram, 2002; Ferger, 2004; McCoy, 2006; Sriram, 2006). Similarly, IFN-
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γ knock-out mice are less susceptible to MPTP-induced neuronal loss and it has been 
reported that dopaminergic neuronal loss may be mediated by IFN-γ (Mount, 2007). 
However, very little is known about the mechanisms involving pro-inflammatory 
cytokines in microglia and astroglia activation during dopaminergic degeneration. It has 
been recently suggested that astrocytes may amplify the neuro-toxic effects initiated by 
microglia in dopaminergic degeneration in vitro, but it is unclear how this intercellular 
crosstalk may actually occur in vivo (Saijo, 2009).  
Astrogliosis and microgiosis have been reported in the SN and striatum of mice 
exposed to MPTP, but subjected to a different time course (Czlonkowska, 2001; 
Breidert, 2002): a notable microglial activation is observed 2 days after MPTP 
treatment, while the astrocytic reaction peaks 5 days after MPTP injection and is less 
transient than the microglial one (Breidert, 2002) (Fig. 4). These two cell types also 
differ in term of the cell proliferation activities, as newborn microglial cells can be 
identified by bromodeoxyuridine (BrdU) labelling in both MPTP-treated mice and 
monkeys, while no BrdU staining is observed in astrocytes (Tandé, 2006; Brochard, 
2009). Therefore, microgliosis involves both increase in the number of microglial cells 
and prominent morphological changes, while astrocytosis is only the result of 
phenotypical change (increased expression of GFAP and morphological changes). So 
far, the role of astrocytes in parkinsonian syndromes is poorly understood, but it can be 
hypothesized that a direct participation of astrocytes to neuronal death initiation is 
unlikely because it takes place too late in the degenerative process. Only a selective 
blockade of the astroglial reaction may help in clarifying the contribution of astrocytes 
in Parkinson’s disease. 
Cells of the peripheral immune system may also play a part in 
neurodegeneration, as observed in different animal models. Kurkowska-Jastrzebska and 
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colleagues (Kurkowska-Jastrzebska, 1999) reported infiltration of T lymphocytes in the 
brains of mice exposed to MPTP and, more recently, a high number of infiltrating 
CD8+ T-cytotoxic and CD4+ T-helper cells in the nigro-striatal pathway after MPTP 
injection in mice has been described (Brochard, 2009). Since no B lymphocytes were 
detected after MPTP exposure, this cell infiltration must be selective for T cells. 
Furthermore, this infiltration selectively targeted the nigro-striatal pathway, as no T 
cells were observed in brain regions not affected by neuron degeneration. T-cell 
transmigration was already evident 2 days after MPTP injection, increasing 
progressively for at least 7 days, to cease after 21 days (Brochard, 2009). Therefore, 
brain infiltration by T cells happens after microglial activation, but precedes astrogliosis 
(Fig. 4). In addition, no intracerebral clonal expansion of T cells was detected, which 
suggested their continuous extravasation and long-term survival in the brain 
parenchyma. By transfer strategies, it has been shown that CD4+ T-helper cells, but not 
CD8+ T-cytotoxic cells, were deleterious for dopaminergic neuron survival, suggesting 
that the adaptive immune system might contribute to neuronal degeneration in the 
MPTP mouse model (Brochard, 2009). The mechanisms involved in such cell-specific 
and region-specific T-cell recruitment are still unknown, but they might involve early 
microglial cell activation and innate neuroinflammatory processes that could modify the 
local microenvironment. The contribution of T cells to dopaminergic neuron 
degeneration supports findings of a recent study, showing that nitrated α-synuclein 
immunity accelerates the degeneration of dopaminergic neurons in the SN (Benner, 
2008). 
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Fig. 4. Sequence of the cellular events occurring in the substantia nigra after MPTP injection in mice. After 
exposure to MPTP, some dopaminergic neurons are affected by the neurotoxin, leading to neuronal distress. This 
distress phase might last a few days (3–4 days) and is followed by destruction and elimination of the affected neuron 
cell body. 7 days after exposure, dopaminergic cell death usually does not progress further. During this time frame, 
microglial cells are rapidly activated (12–24 h after exposure to MPTP), well before the physical destruction and 
elimination of dopaminergic nerve cells. Therefore, microglial cells are probably highly sensitive to mild 
neuropathological changes. The astroglial cell reaction happens later, usually 3–4 days after exposure to MPTP, 
concomitantly with dopaminergic cell death. Infiltration of T lymphocytes into the brain is seen as early as 2 days 
after exposure to MPTP and increases continuously for up to 7 days. The inflammatory reaction of activated 
microglial cells within the substantia nigra might contribute to the site-specific recruitment of these adaptive immune 
cells. MPTP=1-methyl-4-phenyl-1,2,3,6-tetra-hydro-pyridine (Hirsch and Hunot, 2009). 
 
These data from animal models indicate that the mechanism of cell death in the 
nigrostriatal pathway involves non-neuronal cells. An analysis of the molecular factors 
involved in these cellular interactions in MPTP animal models might enable the 
identification of targets able to reduce microglial cell activation and lymphocytic 
infiltration and, hence, neuronal degeneration. Overall, although a large number of 
therapeutic approaches have been tried in the MPTP model, their predictive efficacy in 
humans has been inconsistent (Beal, 2001). Even though the extent to which MPTP-
based models mimic the entirety of the human condition is controversial, they are 
considered a convenient mean to quickly replicate much of the cellular dysfunction seen 
in Parkinson’s disease. 
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Remodeling of brain extracellular matrix in neurodegeneration: what we know about 
metalloproteinases in PD and parkinsonism? 
Compared to systemic extracellular matrix (ECM), the adult brain ECM is unusual in at 
least two respects. First, unlike other organs, the brain exhibits a limited, 
ultrastructurally well-defined, stromal space. Despite the elegant descriptions by 
Camillo Golgi and Santiago Ramon y Cajal at the turn of the previous century, prior to 
the 1970s, it has been generally accepted that brain tissue consists predominantly of 
closely apposed neurons and glia, leaving little room for significant amounts of ECM. 
The advent of several new technologies gradually revised this theory, demonstrating a 
variety of ECM molecules filling significant amounts of ECM space (Yamaguchi, 
2000). Second, common ECM components of systemic organs (eg, fibronectin and 
collagen) are virtually absent from the adult brain ECM, while different types of 
proteoglycans are abundantly expressed and localized within intercellular spaces 
between neurons and glia (Bandtlow, 2000; Yamaguchi, 2000; Dityatev and Schachner, 
2003). In retrospect, what was previously described as a “perineuronal net” (PNN) by 
Golgi and Ramon y Cajal in 1890 is consistent with the “new discoveries” of brain 
ECM. PNNs are reticular networks, constituted by ECM proteins, which embrace the 
surface of neuronal cell bodies and proximal dendrites and fill the space between 
neurons and astrocytic processes. Histologically bland in their appearance, PNNs vary 
in type and distribution, each with a potentially unique molecular structure surrounding 
a wide variety of neurons (Dityatev and Schachner, 2003). This structure includes 
lecticans, hyaluronic acid (HA), tenascin-C and tenascin-R. It is thought that the HA–
lecticans–tenascin complexes deposited on the neuronal surface may form a repulsive 
barrier against approaching axons and dendrites. The absence of synaptic contacts along 
those neuronal surfaces covered by PNNs supports this hypothesis. Although the 
30 
 
physiological role of PNNs has not been fully elucidated, their postnatal appearance 
suggests a role in limiting the development of new synaptic contacts (Yamaguchi, 
2000). PNNs also contain a variety of proteoglycans, the diversity of which dependent 
on the differential expression of genes encoding core proteins, on alternative splicing 
and on transcription–termination, as well as on variations in the length and types of 
glycosaminoglycan (GAG) side chains. Chondroitin sulfate (CS) or heparan sulfate 
(HS) side chains constitute most of the CNS proteoglycans; some of them belong to the 
ECM, while others are ether bound to the cell surface by a transmembrane domain or 
anchored with short tails made of glycosyl phosphatidylinositol (GPI). The ECM 
capacity of binding growth factors via HS and CS modulates their interaction with the 
cell surface. In fact, the localization and biological activity of factors such as the 
fibroblast growth factor (FGF) strongly depend on the presence and composition of the 
ECM, where the differential binding characteristics of specific HS structures can 
potentiate, or inhibit, its biological activity (Bandtlow and Zimmermann, 2000). Other 
growth factor families, i.e. the vascular endothelial growth factor (VEGF) and the 
platelet-derived growth factor (PDGF), are known to bind to heparin/HS, which can 
modulate their biological activities (Raine and Ros, 1992; Neufeld, 1999). 
Brain ECM provides not just physical support to the various cell types herein 
present, but also a local homeostatic control crucial for the survival of differentiated 
neurons, which are believed incapable of regeneration (Dityatev, 2008; Faissner, 2010). 
In addition to the control of a plethora of cell signaling molecules, the ECM can also 
physically buffer ions and neurotransmitters associated with synaptic activity.  
Several studies have shown changes in the ECM associated with 
neuropathological states, but a few studies have really demonstrated a mechanistic 
connection between these changes and neuronal death. Neurodegenerative states can be 
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divided into two groups, based on the major changes in ECM (Fig. 4). The first group 
comprehends age-related progressive neurodegenerative diseases, such as AD, 
characterized by changes in the expression of proteoglycans and by formation of protein 
aggregates and amyloidosis. It is not known whether protein aggregation, or deposition, 
is the primary event, which successively leads to changes in proteoglycan expression, or 
whether the two processes are interconnected. An alternative could be that changes in 
proteoglycans are the primary events that trigger protein aggregation. All these changes 
are, however, accompanied by secondary microglial activation.  
 
 
 
Fig. 4. Possible mechanisms of extracellular matrix (ECM)-related neurodegeneration. Aging or protein 
aggregation accelerated by genetic mutation can be associated with ECM alterations that would result in the co-
deposition of ECM components [eg, heparan sulfate proteoglycans (HSPGs) and chondroitin sulfate proteoglycans 
(CSPGs)]. Those ECM alterations can result in the loss of protective perineuronal nets (PNNs) and increased 
susceptibility to cell death. Dying neurons can induce inflammation, degradation of ECM and induction of a more 
robust inflammatory response. Alternatively, inflammatory-induced neurodegeneration can induce ECM degradation 
through proteolytic activity [eg, matrix metalloproteinase (MMPs) and tissue plasminogen activator (tPA)], induction 
of chemotaxis and microglial activation. The resulting trafficking of inflammatory cells and secretion of cytokines 
can induce neuronal death that would feed the vicious cycle. Abbreviations: MS = multiple sclerosis; HIVD = human 
immunodeficiency virus dementia (Bonneh-Barkay and Wiley, 2009). 
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Up to date, no clear correlation between ECM breakdown and neuronal death is known. 
From the work of Brückener and colleagues (Brückener, 1999; Morawski, 2010) it 
seems that neurons surrounded by PNNs are spared from neurodegenerative changes in 
AD. Breakdown of the PNNs, mostly around parvalbumin-positive neurons, but without 
determining the loss, suggests changes in the neuronal environment that could affect 
their function or susceptibility to further insults.  
The two major systems that regulate brain ECM composition in health and 
diseases are the matrix metalloproteinases (MMPs) and plasminogen activator (PAs)-
plasmine system (Teesalu, 2002; Yong, 2005; Adibhatla, 2008; Bonneh-Barkay, 2009; 
Candelario-Jalil, 2009). MMPs are a large family of more than 20 members, among 
which two collagenases, the metalloproteinase-2 (MMP-2) and metalloproteinase-9 
(MMP-9) are the most abundantly expressed in brain. Synthesized as pro-enzymes, all 
MMPs need the removal of a pro-peptide, which masks the zinc-containing catalytic site 
of the protein, for their enzymatic activation (Page-McCaw, 2007) (Fig. 5). MMPs are 
synchronously expressed with their tissue inhibitors of metalloproteinases (TIMPs), a 
family formed by 4 members, the role of which is highly complex, ranging from MMP 
activation and/or silencing, in strict relation to the their amount and timing of 
production. Activation of MMPs can also be determined by the serine protease plasmin, 
generated by the cleavage of plasminogen by the tissue or urokinase-like plasminogen 
activators (tPA and uPA, respectively) (Michaluk  and Kaczmarek, 2007; Adibhatla, 
2008) functionally linking the two proteolytic systems.  
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Fig. 5. Matrix metalloproteinase family. (a) MMPs are expressed as pro-proteins. A conserved Cys residue in the 
pro-domain coordinates the zinc ion, which would otherwise be used for catalysis. The pro-domain is removed by a 
combination of a cleavage in the domain and a cleavage between the pro-domain and the catalytic domain. (b) Most 
MMPs share a conserved domain structure of pro-domain, catalytic domain, hinge region and hemopexin domain (1). 
All MMPs are synthesized with a signal peptide, which is cleaved during transport through the secretory pathway. 
MMP2 and MMP9 have three fibronectin type II repeats in their catalytic domains (2). Membrane type MMPs (MT-
MMPs) are linked to the plasma membrane either by a transmembrane domain or by a glycosylphosphatidylinositol 
(GPI) linkage, attached to the hemopexin domain (3). Minimal MMPs lack the hinge and hemopexin domains (4). 
MMP21 has a truncated hinge domain. Drosophila melanogaster DmMMP2 has an insertion of 214 amino acids into 
its hinge domain. MMP23 (not shown) has a non-conserved N-terminal domain that consists of an immunoglobulin 
IgC2 domain and a ShKT domain; it is unclear if MMP23 contains a Cys residue switch. (Page-McCaw A, 2007) 
 
PAs are secreted in a precursor form as single-chain polypeptides and in vitro 
are converted by plasmin to active double-chain forms. Regulation of PAs activities in 
the nervous system can occur at multiple levels: transcription, translation, secretion and 
inhibition by anti-proteases (Benarroch, 2007; Zori, 2008; Mitsui, 2008). Despite high 
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levels of tPA mRNA in the hippocampus CA1 region, for example, protein and 
enzymatic assays do not show evidence for tPA presence, suggesting a stringent 
translational control (Salles, 2002). Synaptic signaling can ease this control and lead to 
tPA secretion and activation in the extracellular space. Inhibition of tPA activity is 
under tight control of a variety of anti-proteases of the serpin family (eg, protease-nexin 
1, neuroserpin and plasminogen activator inhibitor 1 (Gualandris, 1996). Some of the 
tPA activities are not linked to plasminogen activation, as tPA can directly cleave the 
NR1 subunit of the NMDA receptor, enhance NMDA-mediated intracellular calcium 
levels and, not ultimately, promote MMP-9 activity up-regulation and ECM degradation 
in response to specific functional inputs, thus ultimately determining synaptic plasticity 
or neuronal degeneration (Madani, 2003). tPA is expressed by both neurons and 
microglial cells, especially in brain regions involved in learning and memory. As the 
activity of tPA in neural tissue is related to neurite outgrowth, regeneration and 
migration, this has suggested that it might be involved in physiological processes 
requiring elevated neuronal plasticity (Melchor and Strickland, 2005). Moreover, the 
tPA/plasmin system can contribute to neuroinflammation. Studies in vitro have 
demonstrated that, under glutamate stimulation, both wild type neurons and microglia 
release tPA, which in turn elicits microglia activation in an autocrine/paracrine manner 
by binding thr annexin II receptor (Siao & Tsirka, 2002). Recently, experiments 
conducted on co-cultures of monocytes and brain endothelial cells showed that 
monocytes induce tPA release by endothelial cells. This subsequently activates the 
extracellular signal-related kinase (ERK1/2) signaling, which is involved in monocyte 
diapedesis (Reijerkerk, 2008).  
MMPs are constitutively secreted; however, they can be trapped at the cell 
surface by either binding to cell adhesion molecules and cell surface proteoglycans or 
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through transmembrane domains (the membrane-type of MMPs, MT-MMP). Another 
subgroup of MMPs comprehend the A disintegrin and metalloproteinases (ADAMs) 
and ADAMs with thrombospondin motifs (ADAMTS) (Page-McCaw, 2007). ADAMs 
are membrane-anchored enzymes that possess both proteolytic and adhesive activities. 
They are involved in the shedding of cytokines, receptors and growth factors from the 
cell surface, as well as in the adhesion to integrins. The TNFα-converting enzyme, or 
ADAM17, is the most characterized protease releasing TNFα from the cell surface 
(Bridges and Bowditch, 2005). ADAMTSs are secreted enzymes involved in the 
cleavage of ECM proteoglycans and in the processing of collagen (Porter, 2005).  
Several secreted MMPs have been shown to contribute to the migratory ability 
of monocytes and in the motility of astrocytes (Vos, 2000; Matias-Roman, 2005; Ogier, 
2006; Sithu, 2007). In brain, they are secreted by neurons, oligodendrocytes, microglia 
and endothelial cells (Lo EH, 2002). Similarly, in the CNS TIMPs are expressed in 
neurons and astrocytes (Crocker, 2004). The abundant expression of some 
metalloproteinase members following nervous system injuries leads to several 
undesirable outcomes, including the breakdown of the blood–brain barrier, the 
development of demyelination (Yong, 2001), as the deposition of purified MMPs in the 
brain parenchyma results in the loss of myelin (Anthony, 1998) and axonal injury 
(Newman, 2001). However, it is not clear whether these outcomes are primary or 
secondary to other processes that develop as the result of the large amounts of MMPs 
released into the brain parenchyma.  
The modulation of neuroinflammation is another significant outcome of the 
changes in metalloproteinase expression, release and activation following nervous 
system injury. Several MMPs can generate encephalogenic fragments from CNS 
proteins, examples of which include the cleavage of myelin basic protein into fragments 
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producing neuroinflammation in animals (Proost, 1993). Many inflammatory molecules, 
such as TNFα, are synthesized as precursors, which require processing by 
metalloproteinase to transform into their active form. On the other hand, MMPs can also 
degrade inflammatory molecules, such as the IL-1β, terminating their activity (Ito, 
1996). By their interaction with chemokines, MMPs also modulate leukocyte trafficking 
into tissues (McQuibban, 2000; Van Den Steen, 2003; Li, 2002; Nagase, 2006). The 
interaction of MMPs and chemokines, besides producing pro- and/ or anti-inflammatory 
signals, can also generate toxic molecules. For example, MMP-2, by removing four 
amino acids from the N-terminus of the chemokine CXCL12, produces a neurotoxic 
species of this chemokine (Zhang, 2003).  
Interaction among proteases can significantly alter the predicted outcome of a 
single proteolytic activity. For example, thrombin and MMP-9 conjunct activities 
mediate the killing of neurons in the mouse brain in vivo (Xue, 2006). Perhaps the most 
significant consequence of the overexpression of MMPs in the CNS is the regulation of 
cell survival and death. Various mechanisms have been proposed to contribute to 
metalloproteinase-mediated cell death (Fig.6) (Yong, 2005).  
The adherence of cells to the ECM provides survival signals through mechanisms that 
include activation of integrin receptors engaged in the linkage with particular ECM 
proteins. When such anchored cells are detached from the substratum, the loss of 
integrin signaling can result in apoptosis, a phenomenon that has been referred to as 
anoikis (‘homelessness’). An advantage of anoikis is that cells that are detached from 
their usual locations do not become the seed of a tumor elsewhere. Therefore, in the 
CNS, the degradation of ECM proteins and the loss of integrin signaling by abnormally 
expressed MMPs affect cell survival (Gu, 2002; Zalewska, 2002). 
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Fig. 6. Interactions between metalloproteinases, cytokines, chemokines and other molecules present at a site of 
injury and their consequences. The expression and activity of metalloproteinases can be up-regulated by 
inflammatory cytokines and chemokines; the elevated protease activity can, in turn, process cytokines and 
chemokines to alter their properties. In addition, metalloproteinase activity can result in the processing of growth 
factors and receptors, free radicals, extracellular matrix (ECM), integrins and other proteins. The net result of these 
interactions includes the alteration of the extent of neuroinflammation, neurotoxicity or survival, and growth and 
regeneration. Therefore, it is not only important to determine whether there is a change in metalloproteinase activity, 
but also whether this affects the interactions of MMPs with other molecules in their microenvironment. ADAM, A 
disintegrin and metalloproteinase; MMP, matrix metalloproteinase; NO, nitric oxide (Yong, 2005). 
 
Notably, the disintegrin domain of ADAMs can also interact with integrins (Bridges & 
Bowditch, 2005) and MMPs can directly engage integrin-mediated signaling (Dumin, 
2001). The direct disruption of survival-promoting components of the ECM, such as 
laminin, can also determine death of ECM-anchored neurons (Chintala, 2002; Gu, 
2005). Besides their direct action, MMPs also interact with other functional molecules 
in their vicinity and alter their properties. An example is the interaction between MMP-
9 and nitric oxide to form a stable S-nitrosylated MMP-9, which is toxic for neurons. S-
nitrosylated MMP-9 has been detected both in vitro and in vivo, in an animal model of 
stroke injury (Gu, 2002).  
Reactive oxygen species produced after CNS injuries might contribute to 
induction and/or activation of MMPs, thereby exacerbating injury, although inactivation 
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of MMPs by oxidants through the modification of amino acids crucial for the enzymatic 
activity can also occur (Parks, 2004).  
Evidences are emerging of long-term effects of MMPs in neurodegenerative 
diseases, including damage to the white matter in patients with vascular cognitive 
impairment, degradation of amyloid peptides in Alzheimer’s disease and apoptosis of 
dopaminergic neurons in Parkinson’s disease. Lorenzl and colleagues (Lorenzl, 2002) 
investigated levels and tissue localization of MMP-2 and MMP-9 in post-mortem brain 
tissue from parkinsonian patients and age-matched control. Results obtained by gel 
zymography on brain areas homogenates, suggested a reduction in MMP-2 levels in the 
SN of PD compared to control cases, while those in the cortex and hippocampus 
remained unaltered (Lorenzl, 2002). MMP-9 levels were always unaffected in all brain 
regions investigated. Furthermore, by immunohistochemistry, it appeared that MMP-2 
was localized primarily in astrocytes and microglia cells, whereas MMP-9 was 
predominantly neuronal. Levels of TIMP-1, one of the endogenous tissue inhibitors of 
MMPs, were also significantly elevated in the SN of PD patient brains versus controls, 
while those of TIMP-2 were unchanged (Lorenzl, 2002). The same authors also 
analyzed MMPs levels in the cerebrospinal fluid of PD patients and in mice acutely 
injected with MPTP, although quality of results is quite discussible (Lorenzl, 2003; 
Lorenzl, 2004).  
Recent studies in vitro have implicated MMPs in the death of dopaminergic 
neurons. Apoptotic dopaminergic neurons release MMP-3, a MMP associated to 
inflammatory processes throughout tissues, which acts as a microglia-activating 
molecule (Mun-Bryce, 2002; Woo, 2008). This suggests that, besides its role in 
degrading extracellular macromolecules, MMP3 is also a signaling molecule, mediating 
the interaction between apoptotic neurons and microglia (Kim, 2005). It has 
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demonstrated that primary mouse mesencephalic cells in culture die when treated with 
BH4 (tetrahydrobiopterin), a selective dopaminergic neuronal toxin; however, treatment 
with the MMP-3 inhibitor NNGH (N-isobutyl-N-[4-methoxyphenylsulfonyl]-
glycylhydroxamic acid) prolongs cell survival by decreasing the release of TNFα from 
activated microglia. These data strongly suggest that microglia, activated by MMP-3, 
causes neuronal degeneration by releasing the pro-inflammatory cytokine TNFα. 
Furthermore, MMP-3 induces dopaminergic neuron apoptosis not only by this TNFα-
mediated extracellular mechanism, but also via intracellular signalling, by activating the 
pro-apoptotic enzyme caspase 3. The mechanisms ruling this intracellular action of 
MMP3 are still unclear (Choi, 2008).  
It has been recently demonstrated that monomeric α-synuclein increases, in a 
dose-dependent manner, both mRNA level and activity of MMP-9, but not MMP-2, in 
cultured rat primary astrocytes and microglia (So, 2010). The maximal stimulation is 
observed in the presence of 50 nM alpha-synuclein. In contrast, tPA activity is 
decreased, with only marginal changes in the level of mRNA encoding tPA, if any. 
Overexpression of α-synuclein in rat primary astrocytes also increases MMP-9 activity 
in the same cell type (So, 2010). MMPs secreted from the α-synuclein–stimulated 
microglia activate the microglia itself by stimulating the protease-activated receptor-1 
(PAR-1) in both autocrine and paracrine manner (Lee, 2010). Other findings obtained in 
vitro in a well-characterized model of pathological α-synuclein aggregation indicate that 
MMP-1 and MMP-3 may also influence the pathogenesis of PD in vivo by the 
generation of specific aggregation-enhancing α-synuclein fragments, which result from 
limited proteolysis (Levin, 2009). Altogether, these data are consistent with the 
possibility that alterations in MMPs/TIMPs levels may contribute to PD pathogenesis. 
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MMPs in neurodegeneration: therapeutic implications 
If MMPs had diverse and widespread functions, what are the prospects for MMP 
inhibitors in the treatment of neurological diseases? This is a complex issue that 
requires careful consideration. MMP inhibitors could be useful in treating acute 
neurological insults, in which the expression of several MMPs is elevated and their 
overall activity detrimental. Such pathological conditions would include stroke and 
spinal cord injury, in which a brief period of treatment with MMP inhibitors could be 
sufficient to reduce the subsequent loss of neurological functions. It is instructive that 
the use of the MMP inhibitor GM6001 for only the first 3 days after spinal cord injury 
in rodents was sufficient to improve neurological functions (Noble, 2002). Similarly, in 
mice, treatment with GM6001 for the first 2 days after hemorrhagic stroke was adequate 
to reduce neutrophil infiltration, oxidative stress, brain edema and neurotoxicity 
(Hwang, 2005). Chronic usage of selective MMP inhibitors in diseases such as multiple 
sclerosis, AD or PD will be more problematic as the long-term application of these 
inhibitors might affect reparative processes, as an eventual re-myelination. Since 
different MMPs may carry out either beneficial or detrimental activities in chronic 
diseases and certain MMPs may exert a different functions depending the phase of the 
disease in which are released, the outcome of targeting MMPs using a non-specific 
inhibitor might be complex. To achieve selectivity of function, the first step should be a 
thorough understanding of the role that MMPs play in the patho-physiology of a given 
disorder, so that the use of inhibitors selective for a single MMPs and administered in a 
time-dependent fashion can be considered.  
Another approach to consider for the block of MMP activity as a therapeutic 
approach in neurodegenerative diseases, is the understanding of the stimulus/i that 
increase the activity of a given MMP, so that its removal or targeting might offer a 
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mean of indirect control of MMP activity (Fig. 7) (Yong, 2005). The inhibition of 
MMPs by using inhibitors, which are selective for individual MMPs, offers another 
level of intervention. The first generations of MMP inhibitors lacked selectivity or 
ability to discriminate between MMPs and ADAMs, however newly generated 
inhibitors are now being chosen for their improved selectivity. Finally, the identification 
of the substrates that mediate the activity of a given MMP in a particular disease could 
be the most crucial endeavor, as these substrates are probably unique for a given 
disease, as reported above. The modulation of the availability of substrates for MMPs, 
as well as the specific targeting of the coupling effectors-substrates, could conceivably 
lend selectivity even if one inhibitor could not target the upstream MMP because of its 
various functions. The methods with which to identify MMP substrates are becoming 
more sophisticated and manageable (Overall, 2004), making it possible to derive means 
of affecting the substrate of interest, so as to block a specific action of a MMP rather 
than targeting the enzyme and all of its associated activities.  
In summary, MMPs are implicated in diseases of the nervous system and it is 
important to target their activity. Although the long-term impact of MMP inhibitors in 
neurological conditions is not clear because of the complexity of MMP function, the 
evidence suggests that the short-term use of inhibitors after acute insults, such as stroke 
and spinal cord injury, will have beneficial outcomes. Genetically modified animals, 
that under-express or over-express MMP, ADAM, and TIMP genes, are being 
developed or are already available. These animal models, coupled with the use of 
selective inhibitors, should aid in unraveling the critical roles they play in the brain, and 
ultimately provide information that will be useful in designing novel agents to reduce 
injury or promote healing.  
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Fig. 7. Multiple ways of targeting metalloproteinases. If the stimuli, including environmental cues, for up-
regulating the expression of MMPs can be identified, these could be removed to normalize the expression of MMPs. 
Various pharmacological inhibitors are available that could be used to target the increase in the content or activity of 
MMPs. At present, many inhibitors are relatively non-specific and fail to discriminate between MMPs and ADAMs. 
However, it is anticipated that pharmacological inhibitors will become more selective, as this is a drug discovery goal 
in the pharmaceutical industry. A perhaps more selective approach to targeting the MMPs is to identify the substrates 
that modulate the action of a particular metalloproteinase in a given context, and to either modulate the availability of 
these substrates or to target the effector pathway that results from them. The ability to inhibit the detrimental aspects 
of MMPs in the CNS while maintaining or even enhancing the beneficial ones will required improved selectivity for 
targeting particular MMPs and their substrates (Yong, 2005). 
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AIM of the PROJECT 
 
PD is characterized by the progressive depletion of the nigro-striatal system, in which 
loss of the SNpc dopaminergic neurons and degeneration of their fibers projecting to the 
striatum induces motor disturbances. Nigro-striatal fiber degeneration in parkinsonism 
is irreversible and the possibility of axon regeneration of the survived neurons is one of 
the main challenges in neuroscience. Studies on the regeneration of spinal cord neuron 
axons have suggested that reorganization of the extra-cellular matrix (ECM) is a crucial 
event for successful fiber growth in the CNS (Larsen, 2003; Yong, 2005). However, in 
PD, the associated inflammatory reaction also requires ECM re-arrangement, therefore 
disfavoring neuronal rescue. Both brain neurons and glial cells (i.e. astrocytes, 
microglia and oligodendrocytes) participate to ECM remodeling by releasing 
extracellular proteinases, as the MMPs, and activation of different classes of 
extracellular proteinases has been described in several neurodegenerative diseases, such 
as multiple sclerosis and Alzheimer disease. The possible role of extracellular proteases, 
and particularly of MMPs, in the etiology of PD is, however, far from being uncovered. 
Data on post-mortem PD human brains and on PD patient serum are not conclusive 
(Lorenzl, 2002) and somehow differ from the results reported in parkinsonian mice 
obtained by MPTP, or 6-HODA, administration (Lorenzl, 2004; Hebert, 2003; Kim, 
2005; Choi, 2008; So, 2010; Lee, 2010). It is, therefore, important to understand 
whether and in which direction MMPs can modulate the progression of parkinsonism 
and of the associated inflammatory reaction. In this thesis work, we used parkinsonian 
mice, obtained by acute administration of the mitochondrial neurotoxin MPTP, to 
thoroughly investigate: a) whether some of the most important extracellular protease 
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systems was involved in the onset and progression of the parkinsonian syndrome and of 
the associated neuroinflammatory reaction; b) the specific role of MMP-9, which 
resulted as the main protease whose activation was significantly modulated in the 
response of the nigro-striatal pathway to MPTP intoxication and the evolution of the 
accompanying neuroinflammatory response. Data obtained in mice were then compared 
with those obtained from the elective animal model of parkinsonism: monkeys 
chronically (1-2 years) intoxicated with MPTP until achievement of stable 
parkinsonism.  
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MATERIALS AND METHODS 
 
Animals 
All animals were housed and handled in accordance with the guidelines laid down by 
the European Convention for the protection of Vertebrate Animals used for 
Experimental and other Scientific Purposes (ets no. 123, June 15th, 2006), by the 
International Primatological Society and by the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (NIH Guide, revised 1996).  
MPTP treatment in mice 
Two-three month-old male mice were used. C57BL/6 mice and B6.FVB(Cg)-
Mmp9tm1Tvu/J mice and their matching wild-type were purchased from The Jackson 
Laboratory. Mice were housed in a special room, separated from the others, with 
adequate temperature (21° C), 12 hours day-night cycle and with food and water ad 
libidum.  MPTP treatment was performed according to the established protocol for acute 
toxin treatment (Hunot et al., 20004). Briefly, mice were injected intra-peritoneum (i.p) 
with 80 mg/kg MPTP·HCl (Sigma-Aldrich, St. Louis, MO, USA) in 0.9% NaCl, 
subdivided in four injections of 20 mg/Kg MPTP-HCl, separated by a 2-h interval from 
one another. Control animals received equivalent injections of saline. Mice were killed 
at established time points (see specific paragraphs) and brains removed and processed 
for different analysis.  
MPTP treatment in Monkeys 
For this study, brain sections from a colony of chronic parkinsonian macaques (Macaca 
fascicularis) were used. Monkeys were chronically treated with MPTP and housed until 
establishment of stable parkinsonism (2-5 years) in the Primate Unit of the University of 
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Murcia. We analyzed brain sections obtained from 6 young adult animals from of both 
sexes. Four animals were treated with weekly low intravenous doses of MPTP (0.3 
mg/Kg), according to Herrero et al., (1993) and Barcia et al., (2003). Each animal 
received different MPTP doses according to the level of parkinsonism reached and their 
susceptibility to the toxin (Table I). Monkeys were observed by different researchers 
after administration of each dose and followed through the progression of the 
parkinsonian syndrome. Motor symptoms were assessed using a previously described 
rating scale ranging from 0 to 25 (Herrero et al., 1993). The degree of disability 
increased normally with every new injection and remained stable for 2 years. MPTP-
treated monkeys showed parkinsonian symptoms with a typical parkinsonian posture 
different degrees of bradykinesia and akinesia and sporadic freezing phenomena; some 
of them showed action tremor, paradoxical kinesia and, occasionally, vertical and 
horizontal saccadic ocular movements. Intoxicated animals showing clear impairment of 
in motor score were classified as parkinsonian. With this classification we obtained a 
population of subjects similar to the scenario occurring in PD patients. Animals were 
sacrificed 2 years after the last MPTP administration. Monkeys not treated with MPTP 
were used as controls. 
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Table 1 
Monkey Sex 
Motor 
Score 
MPTP 
Accumulative dose 
Years after 
MPTP 
   mg/kg  
     
C1 Male 0.0 0 - 
C2 Male 0.0 0 - 
C3 Female 0.0 0 - 
P1 Male 3.5 1.8 2 
P2 Female 4.2 0.9 2 
P3 Male 5.0 1.8 2 
P4 Female 9.2 0.9 2 
A1 Male 0 1,8 2 
     
 
Table 1. Values of the motor score reached by the animals, accumulative dose of MPTP (mg/kg) of each animal and 
the time of sacrifice after the last MPTP dose. C; Control animals, A; Asymptomatic animals, P; Parkinsonian 
animals. 
 
Real Time Reverse transcriptase-Polymerase Chain Reaction 
mRNA levels of extracellular proteases were assessed in control and MPTP-treated 
mouse brains by Real Time Reverse transcriptase-Polymerase Chain Reaction (real time 
RT-PCR). Animals were deeply anesthetized with isoflurane (Merial, Harlow, UK) and 
killed by decapitation at different times after the last MPTP injections: 1 hour (h), 24 h, 
48 h, 72 h, 1 week (wk) and 2wks. Brains were rapidly removed, frozen in liquid 
nitrogen-cooled isopentane and stored at -80 °C until use. Frozen brains were revived in 
a cold saline solution (NaCL 0.9%), placed in a matrix for brain slicing (AgnTho's, 
Lidingö, Sweden) and cut in 1 mm-thick coronal sections. The dorsal striatum and the 
SNpc were removed, according to the mouse brain stereotaxic coordinates (“The Mouse 
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Brain in Stereotaxic Coordinates” Paxinos and Franklin, 2001) (Fig. 1), by excision 
with a thin needle and a punching devise of 0.75 mm of internal diameter (AgnTho's, 
Lidingö, Sweden), respectively. Samples were immediately homogenized for mRNA 
extraction. 
 
Fig. 1. Diagrams of stereotaxic coordinates (A, B) and corresponding Choline Acethyl Transferase immunoreacted 
sections (A’, B’) at the level of which the striatum (caudate-putamen, Cpu in A) and the SNpc (green labeling in B 
and indicated by arrows in B’) are dissected (Paxinos and Franklin, 2000). 
RNA extraction, quantification and reverse transcription 
Total RNA from the SNpc and striatum of 6-8 control mice and for each time point of 
MPTP-treated mice was isolated using the RNeasy Micro kit (Qiagen, Milan, Italy). 
Tissues were homogenized in ice-cold reducing lyses buffer, containing 1% β-
mercaptoethanol, by using a ground-glass micro-homogenizer. After centrifugation (14000 
rpm, at 4 °C for 5’), the supernatants were collected and loaded onto a RNeasy silica 
membrane capable and concentrated RNA was eluted in water. RNA was additionally 
purified by the genomic DNA using the DNA-free kit (Ambion, Austin, TX, USA), 
according to the manufacturer’s instructions. Yield and integrity of the purified RNA were 
cPu 
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assessed by spectrophotometric analysis at 260 nm. RNA was reverse-transcribed as 
previously described (Del Signore et al., 2006) by using the c-DNA synthesis kit (Bioline. 
London, UK). Briefly, 2 µL of Random Primers and 2 µl of deoxynucleotide triphosphates 
(dNTP), included in the reverse-transcription kit, were added to the RNA eluted from the 
Rneasy membrane. The total volume was brought up to 20 µl with bi-distilled water and 
the all mix was first incubated at 65°C for 10 min and then chilled on ice for 2 min. After 
transferring the mix in a tube containing 2 µl of RNase inhibitor, 8 µl of 5 X retro-
transcription (RT) buffer and 0,5 µl of Moloney Murine Leukemia Virus (M-MLV) reverse 
transcriptase, bi-distilled water was added up to a final volume of 40 µl. This second 
reaction mix was incubated at 37°C for 1 h to allow the retro-transcription reaction, at the 
end of which the reverse transcriptase was inactivated by heating at 70°C for 15 min and 
then chilling on ice. c-DNA samples were diluted in bi-distilled water to a final volume of 
100 µl and stored at -20°C until use. 
Real time RT-PCR 
2,5 µl of the obtained cDNA were amplified by real-time RT-PCR in 25 µl of the reaction 
mixture containing 12,5 µl of 2X  SYBR Green JumpStart Taq ReadyMix (Sigma-
Aldrich), 0,25 µl of Internal Reference Dye and 3 µl each specific primer (5 µM final 
concentration Forward + Reverse) (Sigma-Aldrich) using an iCycler iQ Real-Time 
Detection System (Bio-Rad, Milan, Italy). Specific primers (Table 2) were designed by 
using the Beacon Designer software (Premier Biosoft International, Palo Alto, CA, USA) 
and syntesized by Genosys (Sigma-Aldrich). Each sample was amplified in duplicate. 
Amplification was carried out for 30-35 cycles (30 s at 95 °C, 30 s at 62 °C and 45 s at 72 
°C). Amplicons were detected after each elongation step and were analyzed using the 
iCycler iQ software (Bio-Rad). A melting curve was obtained after completion of the 
cycles to verify the presence of a single amplified product. Hypoxantinephospho-ribosyl-
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transferase (HPRT) was used as internal standard (Steel & Buckley, 1993); amplification 
efficiencies of HPRT and of all genes of interest were set to be approximately equal. Data 
were calculated based on the threshold cycle (Ct) and are expressed as fold increases in 
mRNA expression. Comparative expression levels were calculated by the 2–ΔΔCt method 
(Livak & Schmittgen, 2001), which means that the relative gene expression corresponds to 
2–ΔΔCt, where ΔΔCt is: (Ct gene in MPTP-treated samples - Ct HPRT in MPTP-treated 
samples) - (Ct gene in Control samples - Ct HPRT in control samples). Data were analyzed 
using the two-tail Student’s t-test or one-way ANOVA test following a post-hoc analysis 
(followed by Dunnet multiple comparisons tests). The null hypothesis was rejected for  
risk equal to 5%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene (and length of amplicon) Primer sequence (5’- 3’) 
tPA (132 bp) 
 
Forward: 
Reverse: 
 
 
TGGTGCCATGTGATGAAGG 
GGTGATGTCTGTGTAGAGTCC 
Plasminogen (109 bp) 
 
Forward: 
Reverse: 
 
 
ATCGTCCACTACCATCACAGG 
GTTCATCTCCAAGCCAGCATC 
MMP-2 (144 bp 
 
Forward: 
Reverse: 
 
 
AAGAGTTGGCAGTGCAATACC 
CGATGGTGTTCTGGTCAAGG 
MMP-3 (149 bp) 
 
Forward: 
Reverse: 
 
 
GCATTCACACCCTGGGTCTCC 
CCTGGGAAATCCTGGCTCCAT
G 
MMP-9 (137) 
 
Forward: 
Reverse: 
 
 
GGCGTGTCTGGAGATTCG 
ATGGCAGAAATAGGCTTTGTC 
HPRT (160 bp) 
 
Forward: 
Reverse: 
 
 
AGTCCCAGCGTCGTCATTAG 
CCATCTCCTTCATGACATCTCG 
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Table 2. Primers (5’-3’) used for Real-Time RT-PCR. This table shows forward and reverse primer sequences 
with the length of amplified fragments (bp) used in Real time RT-PCR experiments. 
 
Western Immunoblot 
Primary antibodies  
Rabbit polyclonal antibodies against MMP-9 (diluted 1:2000) and tyrosin hydroxylase 
(TH) (diluted 1:1000) were from Chemicon (Temecula, CA, USA). Rabbit polyclonal 
antibodies against tPA (diluted 1:500) and plasminogen (diluted 1:2000) were from 
Innovative Research (Asbach, Germany). Mouse monoclonal antibody against 
Glyceraldehyde-3-Posphate Dehydrogenase (GAPDH) (diluted 1:5000) was from 
Abcam (Cambridge, MA, USA). 
Preparation of tissue extracts 
The SN and striatum from the frozen brains of control and treated mice were dissected 
as described for the real time RT-PCR. Tissues were immediately homogenized with a 
ground-glass micro-homogenizer in ice-cold RIPA buffer, containing 50 mM Tris/HCl 
pH 7.6, 150 mM NaCl, 1 mM EDTA, 1% SDS, 1% Triton X-100, 1 X of a cocktail of 
inhibitors (Sigma-Aldrich, St Louis, MO, USA), 1 mM PMSF, 0.2 mM Na3VO4 and 1 
mM NaF. After centrifugation (15000 X g for 15 min at 4°C), a measured volume of the 
supernatant was analyzed to determine the total protein concentration using the Micro 
BCA kit (Pierce, Rockford, IL, USA). Other aliquots of the supernatant were mixed 
with 4 X reducing loading buffer (200 mM Tris/HCl pH 6.8, 4% SDS, 30% glycerol, 
4% β-mercaptoethanol, 4% blue bromophenol), boiled for 3 min and stored at -20 °C 
until use. 
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Electrophoresis and immunoblotting 
For each sample, 80 µg of proteins were separated on 8% SDS-polyacrylamide gels. 
Molecular mass standard (ColorBurst©, Sigma-Aldrich, St. Louis, MO, USA) 
containing the precisely sized recombinant proteins of 210, 90, 65, 40, 30, 20, 13, 8 
KDa, along with human recombinant gelatinases MMP-9 and MMP-2, tPA or 
plasminogen, used as positive controls, were loaded on separate lanes in the same gel 
with the SN and striatum homogenates. Samples run at constant voltage (200 mV), at 
RT for 1 h. After electrophoresis, proteins were transferred onto a nitrocellulose 
membrane using a transfer buffer composed by 50 mM Tris/HCl, 380 mM glycine, 
0,1% SDS and 20% methanol. Pounceau S staining (Biorad) of the nitrocellulose 
membrane was used to verify the correct electrophoretic migration and the uniform 
protein loading among lanes. Non-specific biding sites were blocked by an incubation in 
5% dry milk (Carnation instant no-fat milk, Nestlé, USA) (DM), diluted in TTBS 1X 
(20 mM Tris/HCl pH 7.5, 500 mM NaCl, 0,05% Tween-20) for 2 h at RT. Membranes 
were incubated overnight, at 4 °C, in either one of the primary antibodies diluted in 3% 
BSA, 0.05% NaN3, in 1 X TTBS. After rinsing twice in 1 X TTBS  and three times in 
2.5% DM in 1X TTBS, membranes were incubated, for 1 h at RT, in the appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody (Promega, Madison, WI, 
USA): either goat anti-rabbit IgG or goat anti-mouse IgG,, diluted 1:10000 and 1:15000 
in 2.5% dry milk in 1 X TTBS, respectively. Antibody binding sites were revealed by 
using an enhanced chemiluminescence (ECL) kit (Pierce, Rockford, IL, USA) and 
exposing the membranes to the Hyperfilm ECL, from GE Healthcare (Waukescha, WI, 
USA). The intensity of the immunopositve bands was evaluated by densitometric 
analysis by using the ImageQuant 5.2 software (GE Healthcare). The optical density 
(O.D., arbitrary gray units) of each band of interest was normalized against the O.D of 
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the band immunopositive for the GAPDH in the same lane, used as the internal 
reference protein. Within each experiment, densitometric values were expresses as the 
ratio of O.D. MPTP treated mice/ O.D. control mice.  
 
In situ zymography 
In order to localize the gelatinolytic activity of MMP-2 and MMP-9 in both SNpc and 
striatum of control and parkinsonian mice, we performed the in situ zymography 
technique on fresh brain cryosections. Animals were anesthetized with isoflurane and 
killed by decapitation. Brain were rapidly removed, frozen on dry-ice and stored at -
80°C until use. After embedding in Tissue-Tek® O.C.T. TM compound, unfixed brains 
were cut encompassing the entire midbrain and striatum in coronal, 10 µm-thick serial 
sections by using a cryostat. Frozen sections were directly mounted on Super Frost 
Ultra Plus® glass slides (Menzel- Gläser, Braunschweig, Germany) and incubated 
overnight at 37 °C in a gelatinase activation buffer made of 50 mM Tris/HCl, pH 7,6, 
150 mM NaCl, 5 mM CaCl2, 0.2 mM NaN3 e 50 µg/ml of DQ™ Gelatin from Pig Skin 
Fluorescein-Conjugated (Molecular Probes, Eugene, OR, USA). Negative controls were 
obtained by adding 20 mM EDTA to the activation buffer. After rinsing in phosphate 
buffer saline (PBS), sections were post-fixed, for 30 min at RT, with 4% formaline in 
PBS. Nuclei were counterstained by incubating the section for 30 min with the blue 
fluorescent probe diamidino-2-phenylindole (DAPI) (1:1000, Invitrogen). Sections were 
rinsed, mounted on glass slides and coverslipped with the ProLong antifade 
(Invitrogen). Sites of proteolytic activities, visible as a fluorescent emission consequent 
to the specific enzymatic cleavage of gelatine by MMPs, were viewed at a Leica 
DMIRE2 confocal microscope (Leica Microsystems, Exton, PA) (see below the 
“Confocal analysis” section). 
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Immunohistochemistry and immunofluorescence 
Mice 
Four to five mice for each experimental condition and time point were used. Mice were 
deeply anesthetized by an intraperitoneal injection of Ketamine (50 mg/kg body weight) 
and Xylazine (50 mg/kg body weight) and perfused transcardially with an oxygenated 
Ringer solution, pH 7.3, followed by 4% freshly depoymerized paraformaldehyde 
(PFA) in 0,1 M phosphate buffer (PB), pH 7,4. Brains were removed and cryo-protected 
in 30% sucrose, at 4 °C, until they sank. Free-floating coronal sections (25 µm-thick), 
encompassing the entire midbrain and striatum, were cut at a cryostat and stored in a 
cryo-protectant (1:1 ethylene glycol and 0,2 M PB, pH 7.4, with addition of 0.5 M 
sucrose) at -20 °C. Free-floating sections were immunoreacted with the following 
primary antibodies: sheep anti-TH (1:1000, Chemicon), in order to visualize and 
quantify levels of the catecholamine biosynthetic enzyme after MPTP treatment; rabbit 
anti- Iba-1 (1:500; Wako, Chuo-Ku, Osaka, Japan), in order identify activated 
microglia, rabbit anti-MMP-9 (1:1000, Chemicon) in combination with either mouse 
anti-NeuN (1:500, Chemicon), used as a neuronal marker, or mouse anti-glial fibrillary 
acid protein (GFAP) (1:500, Chemicon), used as astrocyte marker, or mouse anti-
myelin related protein (MRP) (1:30000, Chemicon), used as oligodendrocyte marker. 
Moreover, in order to localize MMP-9 in microglial cells, a rhodamine-conjugated 
tomato lectin (Griffonia Simplicifolia Lectin I, 1:100, Vector, Burlingame, CA, USA) 
(Pott Godoy, 2008) was used in combination with the anti- MMP-9 immunolabeling.  
 
Monkeys 
Monkeys were sacrificed with a lethal injection of pentobarbital after a pre-anaesthesia 
with ketamine (8mg/Kg body weight) after one, two or five years from the last MPTP 
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injection. Brains were rapidly removed, one hemisphere rapidly frozen on dry ice and 
stored at -80 °C for successive Western immunoblot analysis. The other half was fixed 
for 3 days in 4% freshly depoymerized PFA dissolved in 0.1 M PB, pH 7.4. Fixed 
mesencephalons were sectioned into 40 m-thick serial sections (Vibratome, Leica 
Microsystem, Wetzlar, Germany). Sections of the striatum were immunolabeled with 
the same antibodies used for mice, with the exception of the oligodendrocytes marker 
anti-MRP, which was substituted by a mouse anti-myelin basic protein (MBP) (1:100, 
Chemicon). We were technically unable to co-localize MMP-9 with any of the primate-
specific microglial markers. 
Immunohistochemistry 
Endogenous peroxidases were inhibited by incubating tissue sections in 0.3% H202 and 
10% methanol in PBS, pH 7.4, for 15 min at RT. Antigen retrieval was performed by 
pre-treating sections with citrate buffer, pH 6.0, for 30 min at 65 °C, After a 
permeabilization with 1% Triton X-100 for 5 min, non-specific antibody binding sites 
were blocked with an incubation in 10% normal horse serum (NHS) in 0.1 M PBS, pH 
7.4, for 60 min at RT. Slices were successively incubated for 48 h, at 4 °C and under 
constant shaking, with either one of the following primary antibodies, TH, MRP and 
MBP, diluted in PBS containing 1% NHS, 0.5% Triton X-100, and 0.1% NaN3 
followed by an incubation with either a biotinylated donkey anti-sheep IgG (for TH) or 
donkey anti-mouse IgG (for MRP and MBP) antibodies (Jackson Immuno Research), 
all diluted 1:500 in the same diluent used for the primary antibodies. After 2 hrs at room 
temperature, sections were incubated in the avidin-biotin-peroxidase complex, diluted 
1:100 (ABC kit; Vectastain Elite, Vector Labs, Burlingame, CA, USA) for 30 min at 
RT. Antibody binding sites were revealed by incubating the sections in 0.25 mg/ml 
3,3’-diaminobenzidine (DAB) and 0.03% H2O2 in PBS, pH 7.4, for 10 min at RT. 
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Negative controls were obtained by omitting the primary antibodies. Sections were 
mounted on gelatin-coated slides and dehydrated in a series of ethyl alcohols and xylene 
before being coverslipped. 
Immunofluorescence 
Revelation of MMP-9 by IF was enhanced by using the Renaissance® Tyramide Signal 
Amplification (TSA)-biotin system kit (PerkinElmer). After a pretreatment with citrate 
buffer, pH 6.0 for 30 min at 65°C, and quenching of the endogenous peroxidase 
activity, sections were incubated in a TNB blocking buffer (0.1 M Tris/HCl pH 7.5, 
0.15 M NaCl, 0.5% blocking reagent by the manufacturer), for 1 h at RT. Sections were 
then incubated for 48 hours (at 4°C, under constant shaking) with the rabbit anti-MMP-
9 primary antibody, in combination with either one of the other primary antibodies (see 
above), diluted in TNB blocking buffer, and rinsed 3 x 10 min in TNT buffer (0.1 M 
Tris/HCl pH 7.5, 0.15 M NaCl, 0.05% Tween20) at RT, under agitation. Amplification 
of the signal was obtained by incubating the sections, for 30 min at RT, first with a with 
biotinylated goat anti-rabbit IgG secondary antibody (1:100, Vector Labs, Burlingame, 
CA, USA), diluted in TNB blocking buffer, and then in 1:100 streptavidin–HRP 
conjugate (SA-HRP) (TSA-biotin System kit, PerkinElmer), for 30 min at RT. After a 3 
x 10 min rinse in TNT buffer, the amplification reaction was carry out by incubating 
sections, for 10 min at RT, with a biotinyl tyramide working solution, according to the 
manufactures instruction: 1:50 Biotinyl Tiramide Stock Solution diluted in 1 X 
Amplification Diluent (TSA-biotin System kit, PerkinElmer). The reaction of 
amplification was blocked by rinsing section, 3 x 10 min, in TNT buffer. Finally,  the 
fluorescent signal was obtained by 30 min incubation in the SA-Fluorescein conjugate, 
diluted 1:500 in TNB (TSA-biotin System kit, PerkinElmer). 
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After a thorough rinse in PBS, binding sites between the other primary 
antibodies and their antigens were revealed by incubating sections with the appropriate 
secondary antibodies conjugated with either Alexa Fluor 633 or Alexa Fluor 594 
(1:1000) (Molecular Probes, Carlsbad, CA, USA). After a 3 x 10 min rinse in PBS, 
sections were incubated in DAPI for 30 minutes for nuclear staining. Sections were 
rinsed, mounted on glass slides and coverslipped with the Prolong® Gold antifade 
reagent. 
Confocal analysis 
Fluorescent brain sections were examined using a Leica DMIRE2 confocal microscope 
(Leica Microsystems, Exton, PA) with a 63 X immersion-oil objective and analyzed 
with Leica Confocal Software (Leica Microsystems, Heidelberg 19 GmbH). Optical 
sections were 0.5 μm-thick and a series range for each section was set by determining 
an upper and lower threshold by using the Z/Y Position for Spatial Image Series setting. 
Images could be viewed both as single 0.5 µm-thick planes and layered stacks of planes. 
Confocal microscope settings were established and maintained by Leica and local 
technicians for optimal resolution. (For further details see Barcia, 2006, 2008),  
Quantification and sterological analysis 
SNpc and striatum were identified according to the Monkey Brain Atlas (Paxinos, 1999) 
and The Mouse Brain Atlas in Stereotaxic Coordinates (Paxinos and Franklin, 2001). 
Quantification of HRP-DAB immunolabeled cells in the SNpc was performed on 
coronal sections (two from each monkey and three from each mouse). The number of 
cells was estimated using a system of a computer assisted image analysis, with a Zeiss 
Axioplan 2 microscope connected to a digital camera. The region of interest was located 
at a 1.25 X objective and then One-two images were taken from each brain hemisphere 
using a 20 X objective. Labeled cells were counted in each photographic field and the 
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obtained numbers were expressed as number of cells/mm2. The OD of the TH 
immunolabeling in the striatum was determined by the ImageJ software (Burger and 
Burge, Springer Verlag) and was considered as an index of the dopaminergic density of 
innervation. Both concentrations of the anti-TH antibody and of the DAB solution, as 
well as the time of DAB-H2O2 reaction, were optimized to fall within the linear range of 
the plot of the immunostaining intensities and the scanned OD. Image analysis was 
performed on coronal sections (two from each monkey and three from each mouse) 
using the 1.25 X objective.   
The quantification of MMP-9 co-localization with the different cell markers, as 
well as OL activation, was obtained by confocal microscope analysis. Three 
representative sections of either SN or striatum from every control and MPTP 
intoxicated mouse were chosen and from each one of these, three random images were 
captured. Cells positive for both MMP-9 and another cell marker were counted only 
when the area of co-localization was detected in the majority of the 0.5 µm-thick optical 
layers throughout the entire stack. The density of the different type of cells, which 
expressed MMP-9, was quantified on a single 0.5 µm -thick optical section. The 
obtained results were expressed as the number of double immunopositive cells/mm2. All 
quantifications were done blindly. 
These same parameters were used for quantifying activated OLs in both the 
SNpc and striatum of mice (MRP immunopositive cells) and monkeys (MBP 
immunopositive cells). 
Quantification of activated OLs phenotype in mice 
Sections containing MRP- (mice) were scanned in confocal planes of 0.5 µm along the 
thickness of the section configuring a xyz stack as described above. The rendered 
transparency of the 5 µm stacks was converted by the image software Image-J in black 
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and white images. The area occupied by the total number of OLs present in each 
photographic field (three stacks of images for each animal), taken throughout mice 
SNpc and striatum was measured on these processed images. The area occupied by OLs 
was not measured in monkeys because their processes were completely intermingled 
and the software was unable to distinguish and define each individual cell unit. All 
quantifications were done blindly. 
 
Electron microscopy 
Mice were deeply anesthetized and perfused transcardially with a fixative composed of 
2% freshly depolymerized paraformaldehyde + 2% glutaraldehyde in 0.1 M PB, pH 7.4. 
Brains were removed and the area containing striatal fibres was dissected into 1mm3 
cubes, postfixed with 1% OsO4 and dehydrated in ascending concentration of ethanol 
(50%, 70% and 90%) followed by 90% acetone, before being embedded in Epon 812. 
Ultra-thin sections were cut in an ultramicrotome (Reichert-Imy E Ultracut), collected 
on copper grids and stained with 2% uranyl acetate and 2.5% lead citrate. Sections were 
examined using a transmission electron microscope (Philips TECNAI 12). 
 
Statistical Analysis 
All statistical analyses were performed using either the one-way ANOVA test following 
a post-hoc analysis (followed by Dunnet multiple comparisons tests), or by the 
Student’s t-test, or both. Differences were considered statistically significant for p ≤ 
0.05. All data were always expressed as the mean + standard error of the mean (SEM).  
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RESULTS  
 
Evaluation of MPTP neurotoxicity by TH immunolabeling of the dopaminergic 
pathway 
To test whether MPTP administration was effective in inducing death of the SNpc 
dopaminergic neuron, we studied protein levels and/or localization of TH in the nigro-
striatal pathway of control and MPTP-injected animals by Western immunoblot and 
immunohistochemistry, respectively.  
TH protein levels and immunolabeling in the SN and striatum of control and 
parkinsonian mice 
TH protein levels in the SN and striatum of control and MPTP-treated mice, sacrificed 
1, 24, 48, 72 hrs, 1 and 2 wks after the last injection, were detected by Western 
immunoblot (Fig. 1A, SN; Fig. 2A, striatum) and densitometric analysis of the 
immunopositve bands (Fig. 1A’, SN; Fig. 2A’, striatum) . In the SN, the intensity of the 
TH immunopositive bands, which migrated at the expected molecular mass of 54 KDa 
(Fig. 1A), decreased significantly, respect to control, by 48 hrs after the last MPTP 
injection, remaining lower until 1 wk (Fig. 1A’). This value recovered to control levels 
by 2 wks after intoxication (Fig. 1A, A’). As expected, in the striatum, the decrease in 
protein levels was anticipated with respect to the SN (Fig. 2A), being abruptly and 
significantly decreased by 24 hrs after MPTP injection (Fig. 2A’). Protein levels tended 
to increase by approximately 72 hrs after injection, although they never reached levels 
comparable to control in the considered post-treatment time frame (fig. 2A, A’). These 
results were confirmed by immunohistohemistry, flanked by stereological or 
densitometric evaluation of the immunopositive elements. In the SNpc of control mice, 
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TH immunoreactivity strongly labeled numerous neuronal cell bodies and fibers (Fig. 
1B), which appeared drastically reduced early after MPTP injection (Fig. 1B, 72 hrs) 
and that partially recovered 2 wks later. A stereological study conducted on 
photographic fields including the whole SNpc taken from different brain sections (Fig. 
1B’), further demonstrated that after MPTP administration the number of TH-
immunopositive (TH+) neurons was significantly reduced by half (40-50%) as early as 
24 hrs, reaching the 70-80% after 72 hrs (Fig.1B’). This number recovered slightly after 
2 wks from treatment, remaining however significantly lower than control (Fig. 1B’). 
Loss of TH+ neuron in the SNpc largely reflected that of TH+ fibers, which these 
neurons project to the striatum (Fig. 2B). Densitometric analysis of random areas of the 
striatum of different brain sections confirmed a significant and dramatic decrease in the 
striatal dopaminergic projections 24, 48 and 72 hrs after the MPTP injection (Fig. 2B’). 
However, 2 wks after MPTP treatment, the increase in TH+ fibers in the striatum, was 
comparable to control, despite the reduced number of neurons, suggesting terminal axon 
sprouting of survived neurons and partial rescue of the dopaminergic pathway. 
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Fig. 1. TH expression in the SN of control and MPTP-treated mice. A-A’) TH Western immunoblot (A) and 
relative densitometric analysis (A’) on protein extracts from the SN of control (ctrl) and MPTP-treated mice scarified 
at different time after the last toxin injection. In the representative Western immunoblot shown in A, the TH antibody 
recognizes a protein band of about 54 kDa. GAPDH, shown below, is used as the internal reference protein. 
Molecular mass standards, expressed in kDa, are indicated on the right hand side. A’) Densitometric analysis reveals 
that the intensity of the immunopositive bands decreases significantly, respect to control, by 48hrs up to 1 wk after 
MPTP injection. After two weeks, levels of TH increase significantly respect the previous dates, returning to control 
levels. O.D: optical density. Data are the mean ± s.e.m. of 6-7 animals/experimental group. *p≤0.05, calculated by 
the one way ANOVA Duncan’s test. B-B’) TH-DAB immunolabeling (B) in the SNpc of three representative brain 
sections from control and MPTP-injected mice and relative quantitative analysis (B’). B) Compared to control mice, 
72 hrs after MPTP injection, a drastic decrease in the intensity of the immunolabeling and in the number of 
immunopositive elements (neurons and fibers) is observed. This reduction persists at later dates, although 2 weeks 
after MPTP injection a partial recovery of the immunostaining can be appreciated. B’) Quantitative analysis of the 
TH immunopositive (TH+) cells/mm2 shows a significant decrease, respect to control, by 24h. A partial, but 
significant, recovery is observed 2wks after treatment. n = 4-5 animals/experimental group; bars represent the mean ± 
s.e.m.; *p≤0.05, calculated by the one way ANOVA (Duncan’s test). 
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Fig. 2. TH expression in the striatum of control and MPTP-treated mice. A-A’) TH Western immunoblot (A) and 
relative densitometric analysis (A’) on protein extracts from the striatum of control (ctrl) and MPTP-treated mice 
scarified at different time after the last toxin injection. A) Representative TH western immunoblot, performed on 
striatal protein extracts. A’) Densitometric analysis of the immunopositive bands reveals a significant decrease, 
compared to control, in TH protein levels by 24hrs after MPTP injection. O.D.: optical density. n = 6-8 animals/time 
point; bars represent the mean ± s.e.m. of the optical densities; *p ≤ 0.05 calculated by the one way ANOVA Duncan 
test. B-B’) TH-DAB immunolocalization in striatum of both control and MPTP-injected mice and relative 
densitometric analysis of the immunolabeled areas. B) In the dorsal striatum of control animals, the TH 
immunostaining due to the dopaminergic fibers projecting from the SN is intense. After MPTP injection, a dramatic 
reduction in the density of TH immunopositive fibers is observed (72hrs in B), followed by a partial recovery at later 
dates (2wks in B). B’) The values of the O.D. associated with the TH immunopositive areas statistically confirm these 
observations. n = 4-5 animals/experimental group; bars represent the mean ± s.e.m.;  *p≤0.05, calculated by the one 
way ANOVA (Duncan’s test). 
 
TH immunolabeling in the SN and striatum of control and parkinsonian monkeys 
 Sample sections from the monkey striatum, taken from the different series used in the 
following experiments, were tested in parallel to the mice striatum to evaluate the 
appropriate reduction in TH immunolabeling, as the confirmation of an established 
parkinsonian phenotype. Both SNpc and striatum (caudate and putamen) of control 
animals were characterized by an intense TH immunostaining (Fig. 3B,C, control). 
Comparing the two groups of monkeys (control and MPTP-treated), we observed a 
dramatic decrease in the intensity of immunolabeling in both SNpc and striatum of 
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intoxicated monkeys (Fig. 3B,C, MPTP). Stereological quantification of dopaminergic 
neurons (TH+ cells) in the SNpc confirmed this decrease as significant compared to 
control (Fig. 3B’). A significant decrease in TH-immunoreactivity was also found in 
both caudate nucleus and putamen of parkinsonian animals compared with the 
corresponding areas in control monkeys (Fig. 3C’).  
 
Fig. 3. Persistent TH depletion 
induced by MPTP chronic treatment 
in monkeys. A) Artistic drawing of the 
typical gait posture of a normal monkey 
(control) compared with the 
characteristic parkinsonian posture 
(Parkinsonian). Parkinsonian monkeys 
present an alteration of their gait posture 
characterized by curvature of the trunk 
and rigidity of the limbs, together with 
rigidity of the tail (drawings by C. 
Barcia). B,C) Analyzed areas are 
encircled/boxed in red on the section 
drawings. TH-DAB immunolabeling in 
SNpc (B) and striatum (C) of control 
and parkinsonian monkeys shows an 
evident decrease in the number and 
density of TH+ cells and fibers, 
respectively, in parkinsonian monkeys 2 
years after the last MPTP injection, 
compared to control. B’-C’) These data 
are confirmed by both stereological 
quantification of the number of TH+ 
cells in the SNpc and densitometric 
analysis of areas occupied by TH+ fibers 
in the striatum. Control group: n = 3 
monkeys; Parkinsonian group: n = 5 
monkeys. Histograms represent the 
mean ± s.e.m.; *p≤0.05, **p≤0.01, 
calculated by the student’s t test.  
 
 
 
Evaluation of mRNA levels of components of the PA-plasmin and MMP systems in 
the dopaminergic pathway of parkinsonian mice 
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In the first part of the project we looked for possible changes, in both SN and striatum 
of parkinsonian mice compared to control, in mRNA levels of several components of 
the two most important extracellular protease systems, the PAs-plasmin system and the 
MMPs family, known to play important roles in various physiological and pathological 
brain processes. Through this initial step, we aimed at understanding whether one or 
both systems could be involved in the genesis and/or progression of the selective loss of 
the dopaminergic nigrostriatal pathway induced by MPTP intoxication and of the 
prominent inflammatory reaction to which it associates. 
Study of mRNA levels of tPA, uPA and plasminogen after acute MPTP administration in 
mice 
Real time RT-PCR experiments demonstrated that MPTP acute treatment of mice 
induced a general down-regulation, or no regulation, of the mRNA levels of the major 
components of the PA-plasmin system examined. In the SN, transcript levels of tPA, 
were mainly significantly decreased, respect to control, 48 and 72 hrs after the last 
MPTP injection, as well after 2 wks. However, a significant (about two-fold), but 
transient increase was observed 1 hr after intoxication (Fig. 4A); a second significant 
increase, but much more modest than the first one, was seen at 1 wk. In the striatum of 
parkinsonian mice, tPA mRNA levels were either comparable (1 hr, 24 hr, 1 wk) or 
significantly decreased (48 hr, 72 hr, 2 wks) respect to control mice.  
uPA is the functional analog of tPA, in that it is involved in the cleavage of 
plasminogen into the active serine-protease plasmin, although their levels and 
distribution within various brain regions, as well as their contribution, can vary in 
different processes. A comparative study of uPA and plasminogen (see below) mRNA 
expression between control and MPTP mice was only possible for the SN, as their 
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levels in the striatum of parkinsonian mice were below the sensitivity of the technique. 
uPA mRNA levels remained unchanged, respect to control, after MPTP treatment (Fig. 
4B), while those of plasminogen, more in accord with what observed for tPA, were 
significantly lower at 48-72 hrs and 1 wk (Fig. 4C).  
  
Fig. 4. mRNA levels of components of the PAs-plasmin system in the SN and striatum of control and MPTP-
injected mice. A) After an initial increase 1 hr after MPTP 
injection, tPA mRNA levels in the SN decrease significantly 
respect to control by 48 hrs up to 2 wks, although a slight, but 
significant, increase is observed at 1 wks. A’) In the striatum, 
tPA mRNA levels decrease significantly respect to control 24-
48hrs after MPTP injections, being still significantly lower after 
2 wks. B) uPA mRNA levels in the SN of control and 
parkinsonian mice are not different. C) mRNA levels of 
plasminogen decrease significantly, compared to control, 
between 48-72 hrs and 1 wk after MPTP injections, returning to 
control levels 2 wks later. n=6-8 animals/experimental group; 
bars represent the mean ± s.e.m. of the mRNA levels in MPTP-
treated mice/mRNA levels in control animals. *p ≤ 0.05 
calculated by the one way ANOVA (Duncan’s test). 
 
 
Study of mRNA levels of MMP-2, MMP-9 and 
MMP-3 after acute MPTP administration in 
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mice 
Based on their large expression in brain in both physiological and pathological 
conditions, MMP-2, MMP-9 and MMP-3 were identified as the three proteases, the 
changes of which could be associated to the development of parkinsonism. Analysis of 
the respective mRNA levels (Fig. 5 A-C, SN; Fig. 5 A’-C’, striatum), showed that only 
the expression MMP-9 is consistently and significantly modulated in both SN and 
striatum of parkinsonian mice. In fact, mRNA levels for MMP-2 and MMP-3 
apparently tended to increase transiently in the SN by 24/48 hrs (Fig. 5A, B) and to 
oscillate in an apparent random fashion in the striatum (Fig. 5A’, B’); these difference, 
however, were never significant due to quite large standard errors. This may indicate a 
contribution to the total level of these mRNA by cells incoming (non-resident) into the 
affected areas, or by local cells activated by the noxious stimulus, which express these 
MMPs at various degrees, thus confounding the overall picture. Moreover, MMP-2 and 
MMP-3 mRNAs came out after a higher number of the real time RT-PCR cycles than 
those imposed for MMP-9, which strongly suggests that their levels in these regions is 
quite low and, thus, subjected to a high variability in the final analysis. Differently from 
these, MMP-9 mRNA levels in the SN were about 1.8 and 2.5-fold higher than control 
24 hrs and 48 hrs after MPTP treatment, respectively. In the following experimental 
dates, mRNA levels decreased to values that were no significantly different from 
control, although still higher than this (Fig. 5C). In the striatum, MMP-9 mRNA levels 
were significantly increased respect to control 24 hrs and 1 wk after MPTP injection, 
but significantly decreased at the 48 hrs time point (slightly decreased) and after 2 wks 
(decreased about half of the control) (Fig. 5C’). 
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Fig. 5. Study of MMP-2, MMP-3 and MMP-9 m-RNA levels in the dopaminergic pathways of control and 
parkinsonian mice. A,A’) In the SN (A), mRNA levels of MMP-2 decrease significantly respect the control only 
72hrs after the toxin administration, although they tend to be higher, but not significantly, at 24 and 48 hrs. In the 
striatum (A’), MMP-2 mRNA levels follow little oscillations respect to control, but never statistically significant. 
B,B’) In the SN (B), MMP-3 mRNA levels do not significantly differ from control throughout the post-injection time 
considered, except for the 2wks time point, where they decrease significantly. In the striatum (B’) levels oscillate up 
and down control level, but never significantly. In general, however, standard errors are too large to draw a correct 
progress of these, as well as of MMP-2, mRNA levels. C,C’) MMP-9 mRNA levels increase significantly, compared 
to control, within the first 24h after the last MPTP injection in both SN (C) and striatum (C’). After 48h, while 
mRNA levels in the SN further increase and then return to control levels in the following dates, those in the striatum 
decrease significantly, remaining lower than control. n=6-8 animals/experimental group; bars represent the mean ± 
s.e.m. of the mRNA levels in MPTP-treated mice/mRNA levels in control animals. *p ≤ 0.05 calculated by the one 
way ANOVA (Duncan’s test). 
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Evaluation of tPA, plasminogen and MMP-9 protein levels in the SN and striatum of 
control and parkinsonian mice 
The levels of those proteins, the mRNA of which were seen changing significantly after 
MPTP injection, were successively investigated by Western immunoblot on protein 
extracts from SN and striatum of control and parkinsonian mice. This part of the study 
aimed to uncover possible post-transcriptional regulatory mechanisms in the 
extracellular protease production. 
tPA. The anti-tPA polyclonal antibody used revealed three immunopositive bands of 
approximately 65 kDa, 40 kDa and 30 kDa, which corresponded, respectively, to the 
assembled molecule, formed by a heavy and a light chain, to the sole heavy chain and to 
the sole light chain (Fig. 6A, SN; Fig. 7A, striatum). Identity of the bands was 
confirmed, as they co-migrated with the corresponding protein standard run on a 
separate lane in the same gels. Densitometric analysis of the immunopositive bands 
relative to the whole form of the enzyme, carried out on 6 to 8 different Western blots, 
did not show any significant changes in tPA protein levels, in both SN and striatum 
(Fig. 6 A’, SN; Fig. 7 A’, striatum). 
Plasminogen was recognizable as a single immunopositive band, which co-migrated 
with the corresponding protein standard at a molecular mass of approximately 90 kDa 
(Fig 6B and 7B). In the SN, densitometric analysis of the immunopositive bands 
revealed that protein levels of plasminogen changed in accord to what observed for its 
mRNA, being significantly decreased by 1 hr after MPTP and throughout the post-
injection time, compared with control. At a difference, in the striatum (Fig. 7B’), where 
we were not able to detect reasonable mRNA levels in parkinsonian mice, protein levels 
remained not significantly different from control until 2 wks, when they decreased 
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significantly. However, looking at the bar graphs, the behaviour of the protein levels 
after MPTP injection suggests a post-trasncriptional modulation, characterized by an 
initial decrease (1 hr), followed by a progressive increase at about control levels (48 hrs) 
and by another progressive decrease until 2 wks. Except for this last time point, all the 
other differences were not significant compared to control, due to a high variability 
within each experimental group, as shown by the large standard error bars. 
MMP-9 protein levels changed robustly and significantly in both SN and striatum of all 
MPTP treated groups respect to control. The polyclonal antibody used to reveal MMP-9 
recognized two bands at about 100 kDa and 92 kDa, corresponding to the enzyme pro- 
and active forms, respectively (Fig. 6C, SN; Fig. 7C, striatum). The human recombinant 
MMP-9, used as positive control and loaded on a separate lane in the same gels, gave 
rise to a single immunopositive band corresponding to the active form and migrating 
slightly below the one of the mouse brain extracts. Densitometric analysis of the 
immunopositive bands of both pro- and active MMP-9 revealed a significant increase in 
the protein levels in both SN and striatum, early after the MPTP intoxication (by 24 hrs 
in the SN and 1 hr in the striatum), compared to control (Fig. 6C’, SN; Fig. 7C’, 
striatum). Protein levels of both enzymatic forms remained significantly higher than 
control throughout the post-treatment time considered. 
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Fig. 6. Western immunoblots of tPA (A), plasminogen (plgn) (B) and MMP-9 (C) in the SN of both control and 
parkinsonian mice and relative densitometric analysis (A’-C’). A,A’) The anti tPA antibody reveals three bands 
one of approximately 65 kDa, corresponding to the whole molecule, a second of approximately 40 KDa 
corresponding to the tPA heavy chain (h-tPA) and a third of approximately 30 kDa corresponding to the tPA light 
chain (l-tPA). Recombinant human tPA (first lane on the left) was used as standard.  Densitometric analysis of the 
tPA immunopositive bands shows no differences between control and MPTP-treated mice. B, B’). The anti-
plasminogen antibody recognizes a single band of about 90 KDa, the intensity of which diminishes after MPTP 
treatment. Human recombinant plasminogen was used as standard and loaded in the first lane on the left. 
Densitometric analysis confirms a significant and long lasting decrease in the intensity of the immunopositive bands 
after MPTP injection respect to control. C,C’) Typical MMP-9 western immunoblot. The antibody labels two bands 
at the predicted molecular mass of the pro- (100 kDa) and active (92 kDa) MMP-9. On the right hand side, a 
recombinant human MMP-9 was used as standard, which migrates at a slightly lower molecular mass respect to the 
active form o the mouse MMP-9. Densitometric analysis of the immunopositive bands reveals an early and 
72 
 
significant increase, compared to control, in the protein levels of both pro- and active MMP-9, as early as 24hrs after 
MPTP injection. Protein levels remain significantly higher than control throughout the post-injection time considered. 
Molecular mass standard, expressed in kDa, are indicated on the right hand side. GAPDH was used as internal 
reference protein. O.D.: optical density. n = 6-8 animals/experimental group. In the histograms, bars represent the 
mean ± s.e.m. of the optical densities; *p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test). 
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Fig. 7. Western Immunoblot of tPA (A), plasminogen (plgn) (B) and MMP-9 (C) in the striatum of control and 
parkinsonian mice and relative densitometric analysis (A’-C’). (A, B, C) Typical Western immunoblots for tPA, 
plasminogen and MMP-9, respectively. A’,B’) Densitometric analisys of tPA and plasminogen immunopositive 
bands, respectively. The analysis shows no statistical differences between control and MPTP-treated groups. C’) 
Densitometric analysis of the MMP-9 immunopositive bands reveals that, compared to control, protein levels of both 
pro- and active MMP-9 increase significantly as early as 1hr after MPTP injection and remain significantly higher 
than control during the entire considered post-injection time. Molecular mass standard, expressed in kDa, are 
indicated on the right hand side. GAPDH was used as internal reference protein. O.D.: optical density. n = 6-8 
animals/experimental group; bars represent the mean ± s.e.m. of the optical densities; *p ≤ 0.05 calculated by the one 
way ANOVA (Duncan’s test). 
 
Gelatinase enzymatic activity in control and MPTP-treated mice evaluated by in situ 
zymography 
Increase in gelatinase (MMP-9 and MMP-2) activity after MPTP treatment was 
confirmed by in situ zymography. This technique allows to localize the activity of 
specific proteases directly on unfixed cryo-sections, by incubating tissue slices in the 
presence of the specific enzymatic substrate (in this case gelatin for both MMP-2 and 
MMP-9), conjugated to a quenched fluorochrome (i.e. fluorescein), diluted in an 
activation medium. Sites of protease activity are revealed by a fluorescent emission 
consequent to enzymatic cleavage of the specific substrate.  
In both SN (Fig. 8A) and striatum (Fig. 8B) of control mice, we observed a 
number of cells positive for the gelatinolytic activity. Seventy two hours after MPTP 
treatment (chosen as a representative date of the early post-treatment time), and in 
accord with the data obtained by Western immunoblot, we observed an increase in the 
overall intensity of cellular and extracellular gelatinolytic activity, in both brain areas. 
In addition, the striatum of injected mice was characterized by a prominent increase in 
the extracellular enzymatic activity, suggesting that in this area ECM remodelling by 
gelatinases may constitute a rapid response to the toxic insult. Two weeks after 
treatment, gelatinase activity was still apparently higher than control (not shown). 
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Control slices, treated by adding EDTA to the incubation medium, were negative (not 
shown), confirming the gelatinolytic nature of the staining. 
 
Fig. 8. In situ zymography in the SNpc (A) and striatum (B) of control and MPTP-treated mice. In both areas, 
cellular and extracellular gelatinolytic activity increased 72 hrs after MPTP treatment. The extracellular increase is 
particularly evident in the striatum (B). Nuclei are stained in blue with DAPI. 
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MMP-9 immunolocalization and stereological analysis in control and parkinsonian 
mice, alone and in combination with cell specific markers 
After corroborating, by a biochemical approach, that in mice MMP-9 synthesis and 
activation was up-regulated during the period of 2 wks following MPTP acute 
administration, we analyzed which cell type/s contributed to MMP-9 synthesis and 
activation in brain of both control and parkinsonian animals. At this purpose we 
performed a detailed analysis of confocal immuno-microscopy, in combination with a 
stereological quantification of the positive cells, on serial brain sections of control and 
MPTP-injected mice, immunolabelled for MMP-9 alone or in combination with NeuN 
(neuronal marker), GFAP (astrocyte marker), tomato lectin (labelling microglia) or 
MRP (oligodendrocyte marker). Important piece of our investigation was also to 
quantify the inflammatory reaction triggered by MPTP treatment, in which astrocytes 
and microglia are mainly involved, paying attention to a poorly unravelled aspect: the 
oligodendrocyte reaction associated to the partial depletion of the dopaminergic system.  
MMP-9/NeuN/TH triple immunofluorescence in SNpc of both control and MPTP 
injected mice 
In order to demonstrate whether MMP-9 was synthesized by dopaminergic neurons of 
the SN and whether there were differences in the enzymatic expression between these 
and non-dopaminergic neurons, we performed a triple immunofluorence for MMP-9 in 
combination with both NeuN and TH, on both control and MPTP-treated mice.. As 
shown in Fig. 9A, MMP-9 largely co-localized with NeuN and TH, in both 
experimental conditions, labelling numerous cell bodies and axons. Stereological 
quantification of the immunopositive cells showed that almost all neurons NeuN+ and 
TH+ were also MMP-9+ (Fig. 9 B’,B’’) and that the majority of the NeuN+ neurons were 
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dopaminergic (Fig. 9B’”), in both control and parkinsonian mice. Extracellular 
immunopositive spots were also visualized in all confocal pictures taken from both 
control and treated mice, possibly identifying with both axons cut through their 
transversal plane and free, secreted MMP-9. As also previously described, MPTP-
treatment led to a significant loss of TH+ neurons (Fig. 8B’’, gray bar), with the 
consequent reduction in the number of NeuN+ cells (Fig. 8B’, gray bar). As expected 
this reduction partially recovered 2 wks after MPTP administration, along with a 
corresponding increase in NeuN+ cell number (Fig. 8B’,B’’). The number of MMP-
9+/NeuN+ and MMP-9+/TH+ double-labeled neurons, as well as that of MMP-9+ cells 
(Fig. 8B) followed the same time course, being lower than control between 24-72 hrs 
after the last MPTP injection and partially, but significantly recovering after 2 wks. 
Concomitantly, an increase in the extracellular MMP-9 immunopositivity was observed 
(Fig. 8A). From this stereological study also emerged an interesting data: while the 
number of MMP-9+/TH+ neurons significantly diminished after MPTP treatment, with a 
trend similar to the one observed for MMP-9+/NeuN+ cells (Fig. 8B’,B’’), the number of 
the sole non-dopaminergic neurons remained stable and those expressing MMP-9 
(NeuN+/TH-/MMP-9+) increased significantly 72 hrs after the MPTP injection (Fig. 
8B’’’). These results suggest that factors possibly released by dying dopaminergic 
neurons may trigger MMP-9 synthesis in the surrounding non-dopaminergic neurons, in 
response to the neurotoxic insult. 
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Fig. 9. Co-immunolocalization of MMP-9 (green), NeuN (purple) and TH (red) on SNpc sections of control and 
MPTP injected mice and relative stereological analysis. A) MMP-9 largely co-localizes with both dopaminergic 
and non-dopaminergic neurons (arrowhead in the merge panel). MMP-9 immunolabeling is observed in both 
neuronal cell bodies and axons (arrow in the merge panel of control group). Nuclei are stained in blue with DAPI. (B) 
Stereological quantification of MMP-9+ cells (gray bar) and MMP-9+/NeuN+ double labeled cells (white bar). (B’) 
Stereological quantification of NeuN+ cells (gray bar) and MMP-9+/NeuN+ double labeled cells (white bar). (B’’) 
Stereological quantification of TH+ cells (gray bar) and MMP-9+/TH+ double labeled neurons (white bar). (B’’’) 
Stereological quantification of NeuN+/TH- neurons (gray bar) and MMP-9+/TH- neurons (white bar). n = 3 
animals/experimental group; bars represent the mean ± s.e.m. of the cell number/mm2; *p ≤ 0.05 calculated by the 
one way ANOVA (Duncan’s test). 
 
MMP-9/NeuN co-localization in the striatum of control and MPTP-injected mice 
As observed in the SNpc, in the striatum of both control and MPTP treated animals, 
MMP-9 immunnolabeling largely, but not completely, co-localized with the neuronal 
marker NeuN (Fig. 10A). In fact, as shown in the enlargement of the boxed detail of 
Fig. 10A (right-hand four panels), not all neurons were immunopositive for MMP-9 and 
not all MMP-9+ cells were neurons. Seventy-two hours after the last MPTP injection, a 
clear increase in both MMP-9 cellular and extra-cellular staining was observed, 
according to both Western immunoblots and in situ zymography data (Fig. 7C and Fig. 
8B, respectively). Stereological analysis conducted on random striatal photographic 
field (Fig. 10B) confirmed that the number of MMP-9+ cells increased significantly 
respect to control by 48 hrs after MPTP injection and throughout the following dates. 
However, the number of MMP-9+ neurons did not change after treatment, as well as the 
number of NeuN+/MMP-9+ neurons, suggesting that in the striatum the increase in 
MMP-9 may derive from the contribution of other cell types rather than neurons. 
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Fig. 10. MMP-9/NeuN immunofluorescence in the striatum of control and MPTP-injected mice and relative 
quantitative stereological study. (A) Confocal images reveal a large co-localization of the two proteins in both 
control and treated mice, although not all neurons are MMP-9+ (arrow in the enlargement of the boxed area in A, at 
the right hand side). Both cellular and extracellular labeling for MMP-9 are increased respect to control after MPTP 
administration. Green channel: MMP-9, Purple channel: NeuN, Blue DAPI staining: nuclei. (B) Stereological 
quantification show a significant increase in the number of total MMP-9+ cells (blue bars), by 48 hrs after toxin 
injection up to the last experimental date of 2 wks, but not determined by neurons.. Actually, the number of MMP-
9+/NeuN+ cells (white bar) remains stable in all experimental groups. n = 3 animals/experimental group; bars 
represent the mean ± s.e.m. of the cell number/mm2; *p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test). 
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MMP-9/GFAP co-localization in the SNpc and striatum of control and MPTP-injected 
mice 
Double immunolabeling for MMP-9 and the astrocyte marker GFAP was performed on 
sections of the SNpc (Fig. 11A) and striatum (Fig. 12A) of both control and MPTP-
treated mice. As first observation, both areas showed a massive astrogliosis after MPTP 
injection: astrocyte activation was characterized by an increase of their number, size and 
cell processes GFAP+ (Fig. 11A, SNpc; Fig 12A, striatum; red channel). More in detail, 
stereological quantification of MMP-9+, GFAP+ and GFAP+/MMP-9+ cells in both 
SNpc and striatum, demonstrated a significant increase in the GFAP+ cell number by 24 
hrs post-injection and throughout the post-injection time considered (2 wks) (Fig. 11B, 
SNpc; Fig.12B striatum). The number of double labelled GFAP+/MMP-9+ cells 
represented only a small percentage of the entire MMP-9+ cell population. Actually, 
GFAP+ cell bodies were rarely fully stained for MMP-9 (see enlargement of the boxed 
areas in Figs. 11A and 12A, at the left-hand side), but MMP-9 labelling occurred as 
puncta sparsely associated with the cell processes of activated astrocytes (Fig. 11A, 
SNpc: Fig. 12A, striatum; enlargement of the boxed areas, at the left-hand side). 
Stereological analysis revealed a significant increase, in both SNpc and striatum, in the 
number of the GFAP+/MMP-9+ cells throughout the period of 2 wks following MPTP 
intoxication compared to control, starting from 24 hrs and 48 hrs, respectively. 
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Fig. 11. Confocal images of MMP-9/GFAP double immunofluorescence and relative quantitative stereological 
analysis in the SNpc of control and MPTP-treated mice. A). After MPTP injection, both size and number of cell 
processes of astrocytes increase. On the left hand side, the enlargement of the boxed area evidencing a detail of the 
co-localization between MMP-9 and GFAP, is shown. Nuclei were counterstained with DAPI (blue) B) Stereological 
quantification of MMP-9+ (blue bars), GFAP+ (gray bars) and MMP-9+/GFAP+ cells (white bars) reveals that MPTP 
treatment determines a significant increase in both GFAP+ and MMP-9+/GFAP+ cells number. n = 3-4 
animals/experimental group; bars represent the mean ± s.e.m. of the cell number/mm2; *p ≤ 0.05 calculated by the 
one way ANOVA (Duncan’s test). 
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Fig. 12. Confocal images of MMP-9/GFAP double immunofluorescence (A) and relative quantitative 
stereological analysis (B) in the striatum of control and MPTP-treated mice. A) After MPTP treatment, a 
prominent astrogliosis is observed (red channel). The enlargement, at the left side, of the boxed area shows MMP-9 
co-localization with a GFAP+ cell body. Often puncta of MMP-9 immunoreactivity are present along the 
characteristic processes of activated astrocytes (arrows in the merge panel of the MPTP group). Nuclei are 
counterstained in blue with DAPI. (B) Stereological quantification of MMP-9+ (blue bars), GFAP+ (gray bars) and 
MMP-9+/GFAP+ cells (white bars) reveals that MPTP treatment determines a significant increase in both GFAP+ and 
MMP-9+/GFAP+ cells number. n = 3-4 animals/experimental group; bars represent the mean ± s.e.m. of the cell 
number/mm2; *p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test). 
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MMP-9/ lectin Griffonia Simplicifolia (GSA) co-localization in the SNpc and striatum of 
control and MPTP-injected mice 
Microglia are the main modulators of inflammation in brain and in the mouse MPTP 
model of parkinsonism, it has been demonstrated that activated microglial cells undergo 
morphological changes (Depino et al., 2003). We, therefore, investigates whether 
MMP-9 was expressed and/or modulated by MPTP-activated microglia, by staining 
sections of both SNpc and striatum of control and treated mice with a classical 
microglia marker, the Griffonia Simplicifolia Lectin I, Isolectin B4 (GSA) (Pott Godoy, 
2008), alone and in combination with MMP-9 immunofluorescence. Fluorescent 
microscopy analysis (Fig. 13A, SNpc; Fig. 14A, striatum) revealed that MPTP 
treatment triggered microglia activation in the entire nigro-striatal pathway. In both 
control mouse SNpc and striatum, GSA staining was generally weak, mainly as 
associated to small cells characterized by few, thin processes (Fig. 13A, SNpc; Fig. 
14A, striatum; arrows in red channel panels). After MPTP injections, the intensity of the 
GSA staining increased and microglial cells assumed an amoeboid-like feature, with a 
round-shaped perikaryon with short, thick and stout processes (Fig. 13A, SNpc; Fig. 
14A, striatum; red channel). The quantitative stereological study conducted in both 
areas (Fig. 13B, SNpc and 14B, striatum), showed that, in our model, microglia 
activation was associated to a significant increase in the number of GSA+ cells, by early 
after the treatment (24 hrs). The number of positive cells further increased up to 72 hrs 
post-injection and then significantly decreased, compared to this date, after 2 wks, 
although remaining higher than control. Even if microglia activation was observed 
along the entire nigro-striatal dopaminergic pathway, in the SNpc this phenomenon 
appeared exacerbated, probably because of the contiguity with dying neurons.  
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In control mice, we rarely found microglial cells immunopositive for MMP-9; however, 
the number of MMP-9+/GSA+ double labelled cells significantly increased, respect to 
control, after MPTP treatment, in both SNpc (Fig. 13 B) and striatum (Fig. 14B). 
Interestingly, while in the striatum of all MPTP experimental groups the number of 
MMP-9+ microglial cells was always higher than that in control mouse striatum, (Fig. 
14B) in the SNpc it was significantly higher only 48 hrs and 72 hrs after the last MPTP 
injection, dates in which neuronal loss reached its peak (Fig. 13B). However, as for 
astrocytes, stereological quantification performed in both areas (Fig. 13B, SNpc and 
14B, striatum) outlined as microglia was only a minority of the totality of MMP-9+ 
cells.  
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Fig. 13. GSA staining combined with MMP-9 immunofluorence in the SNpc of control and MPTP-injected 
mice and relative quantitative stereological analysis. A) Sections of SNpc immunolabeled for MMP-9 (green) 
combined with GSA staining (red). In control mice, microglia is weakly stained by GSA and is characterized by 
small perikarya with a few, thin processes (arrows in red channel panel). After MPTP treatment, microglia switches 
to an activated phenotype, characterized by increased cell size with thick and stout processes. Double 
immunopositive cells were more often found respect to control (enlargement of the boxed area, at the left hand side). 
Nuclei were counterstained with DAPI (blue) B) Stereological quantification of MMP-9+ (blue bar), GSA+ (gray bar) 
and MMP-9+/GSA+ (white bars) cells reveals a significant increase in the number of both GSA+ and MMP-9+/GSA+ 
cells after MPTP injection (48-72 hrs). n = 3-4 animals/experimental; bars represent the mean ± s.e.m. of the cell 
number/mm2; *p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test).  
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Fig. 14. GSA staining combined with MMP-9 immunofluorence in the striatum of control and MPTP-injected 
mice (A) and relative quantitative stereological analysis (B). A) In control mice, MMP-9 (green) poorly co-
localizes with GSA+ (red) cells. After MPTP treatment, microglia takes the typical activated morphology, and the 
number of double positive cells increases respect to control. As shown in the enlargement of the boxed area at the left 
hand side, MMP-9 clumps of staining in GSA+ cells are frequently polarized. Arrows in  the red channel indicate 
cells with the typical inactive microglial morphology. Nuclei are counterstained with DAPI (blue). B) Stereological 
quantification of MMP-9+ (blue bar), GSA+ (gray bar) and MMP-9+/GSA+ (white bars) cells reveals that MPTP 
treatment determines a significant increase in the number of both GSA+ and MMP-9+/GSA+ cells along the entire 
period of observation. n = 3-4 animals/experimental group; bars represent the mean ± s.e.m. of the cell number/mm2; 
*p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test). 
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MMP-9/MRP co-localization in the SNpc and striatum of control and MPTP-injected 
mice 
In order to complete our study, we investigated the level of co-localization between 
MMP-9 and MRP, an OL marker. In both SNpc and striatum of control mice, OLs were 
characterized by a small cell size with a few or no evident branches processes (Fig. 
15A, SNpc; Fig. 16A, striatum). In MPTP-treated mice, confocal analysis revealed a 
series of important OL morphological changes during the critical period of 
dopaminergic neuron death. Actually, after toxin treatment, OL cell body size increased 
compared to control, showing a higher number of processes with increased thickness, 
which could also reach higher levels of arborization (Fig. 15A, SNpc; Fig. 16A, 
striatum; red channel). Altogether, these features are usually related to an OL activation, 
also known as oligodendrogliosis. OL activation has been described in several 
neurodegenerative diseases, but its role in PD is unknown, as data on both post-mortem 
PD human brains and on PD animal models are not conclusive (Takagi, 2007; McGeer 
and McGeer, 2008). We, therefore, decided to first characterize in detail this 
phenomenon and, because of the novelty of the results, we will describe them in a 
separated session of this thesis. 
MMP-9/MRP co-localization was investigated by confocal analysis. In the 
nigro-striatal pathway of control mice, MMP-9 rarely co-localized with MRP, however, 
following MPTP treatment, the number of MMP-9+/MRP+ significantly increased by 24 
hrs after the last injection, remaining higher than control up to 72 hrs. Two weeks after 
MPTP treatment, while the number of MMP-9+/MRP+ in the SNpc returned to control 
levels (fig. 15B) after the one in the striatum remained higher than control (Fig. 16B). 
As a general observation, MMP-9+/MRP+ cells appeared smaller and morphologically 
less characterized than the neighboring MMP-9-/MRP+. As for astrocytes, MMP-9 
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staining never filled the entire OL cytoplasm, being characteristically distributed in 
patches and small puncta (Fig. 15A, SNpc; Fig 16A, striatum; enlargement of boxed 
areas, at the left-hand side). 
 
Fig. 15. Confocal images of MMP-9/MRP co-localization in the SNpc of both control and MPTP-injected 
animals (A) and relative stereological quantification (B). (A) In control mice, MMP-9 (green) rarely co-localizes 
with MRP (red). In MPTP-treated mice, double immunopositive cells are more frequently encountered and often the 
staining for the two proteins is localized in different cytoplasmatic compartments (enlargement of the boxed area at 
the left hand side). After MPTP treatment, MRP staining increases and OL morphology switches to an activated state. 
Nuclei are counterstained with DAPI (blue). B) Stereological quantification of MMP-9+ (blue bar), MRP+ (gray bar) 
and MMP-9+/MRP+ (white) cells reveals a significant increase in both MRP+ and MMP-9+/MRP+ cell number after 
MPTP treatment respect to control. The number of double immunopositive cells returns to control levels after 2 wks. 
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n = 3-4 animals/experimental group; bars represent the mean ± s.e.m. of the cell number/mm2; *p ≤ 0.05 calculated 
by the one way ANOVA (Duncan’s test).  
 
 
 
Fig. 16. Confocal images of MMP-9/MRP co-localization in the striatum of control and MPTP-injected mice 
(A) and relative stereological quantification (B). A) In the striatum of control mice, MMP-9 (green)/MRP (red) co-
localization is almost null, and MRP+ cells are characterized by small cell body with a few, thin processes. In MPTP-
treated mice, the number of double immunopositive cells increase respect to control, concomitantly with a prominent. 
oligodendrogliosis. MMP-9 immunostaining co-localizes with both small and poorly activated OLs (yellow arrow in 
A), but numerous MMP-9+ puncta are be observed along process arborizations after MPTP treatment (arrows in 
merge panel). Nuclei were counterstained with DAPI (blue). B) Stereological quantification of MMP-9+ (blue bars), 
MRP+ (gray bars) and MMP-9+/MRP+ (white bars) cells show a significant increase in both MRP+ and MMP-
9+/MRP+ cell number after MPTP treatment with respect to control. MMP-9+/MRP+ cell number, returns to control 
levels 2 wks after the last MPTP injection. n = 3-4 animals/experimental group; bars represent the mean ± s.e.m. of 
the cell number/mm2; *p ≤ 0.05 calculated by the one way ANOVA (Duncan’s test).  
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MMP-9 immunolocalization and stereological analysis in control and parkinsonian 
monkeys, alone and in combination with cell specific markers 
If from one side, the mouse model of parkinsonism had the advantage of a fast analysis 
of the cellular and molecular processes related to the nigro-striatal pathway 
degeneration, on the other hand, the use of monkeys was extremely important for better 
understanding the role that inflammatory processes and glial cell reaction, along with 
MMP-9 activation, may have in the long-term disease progression, as it occurs in 
humans. At this purpose, monkey brain sections were immunolabeled for MMP-9 alone 
and in combination with either NeuN, GFAP or MBP, and then analyzed at the confocal 
microscope. This allowed us, along with a quantitative stereological analysis, to 
describe accurately the pattern of MMP-9 expression in the non-human primate model. 
For this part of the study, only brain sections from monkey striatum were available, 
which however were the most useful considering the cellular pattern of expression of 
MMP-9 in mice.  
MMP-9/NeuN co-localization in the striatum of control and MPTP-injected monkeys 
In the striatum of control and parkinsonian monkeys, MMP-9 immunolabeling largely 
co-localized with the neuronal marker NeuN (Fig. 17A, caudate; Fig. 17B, putamen; 
enlargement of boxed areas at the left-hand side) although, as observed in the mouse 
brain, MMP-9- neurons were also present. MPTP treatment induced an increase in 
MMP-9 immunolabeling in both caudate and putamen, respect to control, at both 
cellular (number of immunopositive cells) (Fig. 17A,B, A’ and B’) and extracellular 
(Fig. 17A,B) levels. This increase paralleled that in the number of NeuN+/MMP-9+ 
double labeled neuron (Fig. 17A’,B’). The total number of NeuN+ neurons, instead, 
remained comparable to control, indicating new MMP-9 expression by striatal neurons, 
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which were previously immunonegative. A large MMP-9+NeuN- population, constituted 
by cells with a glial morphology (Fig. 17A,B) and that was not observed in control 
monkey striatum, was also distinguishable. 
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Fig. 17. MMP-9/NeuN co- immunolocalization in the caudate (A) and putamen (B) of control and MPP-treated 
monkeys and relative stereological quantification (A’ and B’). MMP-9 (green) staining in both control and treated 
animals co-localizes with NeuN (violet). On the left hand side, the enlargements of the boxed area are shown. In 
parkinsonian monkeys, MMP-9 staining increases respect to control and it is largely associated with non-neuronal 
cells characterized by a glial morphology. Nuclei are counterstained with DAPI (blue). A’,B’) Caudate (A’) and 
putamen (B’) stereological quantifications of MMP-9+ (blue bars), NeuN+ (gray bars) and MMP-9+/NeuN+ (white 
bars) cells. Control group: n = 3 animals; Parkinsonian group: n = 5. Histograms represent the mean ± s.e.m. of the 
number of cells/mm2; *p≤0.05, ***p≤0.001 calculated by the student’s t test.  
 
MMP-9/GFAP co-localization in the striatum of control and MPTP-injected monkeys 
Double MMP-9/GFAP immunolabeling was performed on striatum sections (Fig. 18A, 
caudate; Fig. 18B, putamen; enlargement of boxed areas at the left-hand side) of both 
control and MPTP-treated monkeys to ascertain MMP-9 expression by astrocytes. 
Section examination at a confocal microscope showed a massive increase in activated 
astrocytes after MPTP treatment respect to control, in both striatal areas. Astrocyte 
activation was characterized by an increase in both cell size and number of cell 
processes of GFAP+ cells (Fig. 18A, caudate; Fig. 18B putamen red channel). Besides 
morphological changes, quantitative stereology performed on random photographic 
fields of the striatum, disclosed a significant increase in the number of GFAP+ cells (Fig 
18A’,B’) in parkinsonian monkeys respect to control. Immunolabeling was 
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preferentially localized in both cell bodies (enlargement of the boxed areas of Fig. 
18A,B, at the left- hand side) and processes (arrows in Fig. 18A,B and enlargement of 
the boxed areas, at the left- hand side) of activated astrocytes. In general astroglia 
represented only a small percentage of the MMP-9+ cells, in both control and 
parkinsonian monkeys, although MPTP treatment significantly increased this value 
(Fig. 18A’,B’).  
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Fig. 18. MMP-9/GFAP co-immunolocalization in the caudate (A) and putamen (B) of control and MPP-treated 
monkeys and relative stereological quantification (A’,B’). In control animals, GFAP staining (red) is weak and it 
is associated with small-sized cells with a few, thin processes. In parkinsonian monkeys, years after intoxication, a 
prominent astroglial reaction is still present. Activated astrocytes present increased cell sizes and numerous, thick, 
complex processes. The number of MMP-9+ (green)/GFAP+ (red) cells is low in both control and treated monkeys. 
MMP-9 staining associates to cell bodies (enlargements of the boxed area at the left hand side) and/or to cell 
processes (arrows) of activated astrocytes. Nuclei were counterstained with DAPI (blue). A’,B’) Caudate (A’) and 
putamen (B’) stereological quantifications of MMP-9+ (blue bars), GFAP+ (gray bars) and MMP-9+/GFAP+ (white 
bars) cells. Control group: n = 3 animals; Parkinsonian group: n = 5. Histograms represent the mean ± s.e.m.; 
*p≤0.05, **p≤0.01, ***p≤0.001 calculated by the student’s t test.  
 
MMP-9/ MBP co-localization in the striatum of control and MPTP-injected monkeys 
Finally, we performed double immunolabeling for MMP-9 and MBP, an OL marker, on 
sections of striatum of both control and parkinsonian monkeys. In both caudate (Fig. 
19A and enlargement of the boxed area, at the left-hand side) and putamen (Fig. 19B 
and enlargement of the boxed area, at the left-hand side) of control monkeys, MBP 
immunoreactivity appeared as a weak extracellular staining with only a few, small 
immunopositive cells. In the same areas of parkinsonian monkeys, the extracellular 
staining was more intense than control and several MBP+ cells showed an increase in 
their cell size. As in the case of mice, these signs could be ascribed to the condition of 
oligodendrogliosis. An accurate description of these aspects is reported in the next 
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paragraphs of this session. Quantitative stereological analysis (Fig. 18A’, caudate; Fig. 
18B’, putamen) showed a significant increase, in MPTP-injected monkeys respect to 
control, in both MBP+ cells, confirming OLs activation, and double MBP+/MMP-9+ 
cells, making these cells the second major cell population after neurons expressing 
MMP-9.  
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Fig. 18. MMP-9/MBP co-immunolocalization in both caudate (A) and putamen (B) of control and MPTP-
treated monkeys and relative stereological quantification (A’,B’). MBP staining (red) in controls animals is weak 
and mainly localized extracellularly. In parkinsonian monkeys, years after the intoxication, it is still possible to 
observe a sustained MBP cellular and extracellular staining, indicating active OL reaction. The number of MMP-9+ 
(green)/GFAP+(red) cells is low in control monkeys, but it clearly increase in MPTP-treated monkeys, in both striatal 
regions. On the left hand side, enlargements of the boxed areas representing MMP-9/MBP co-localization are shown. 
Nuclei are counterstained with DAPI (blue). A’,B’) Caudate (A’) and putamen (B’) stereological quantifications of 
MMP-9+ (blue bars), MBP+ (gray bars) and MMP-9+/MBP+ (white bars) cells. Control group: n = 3 animals; 
Parkinsonian group: n = 5. Histograms represent the mean ± s.e.m. of the number of cells/mm2; **p≤0.01, 
***p≤0.001 calculated by the student’s t test.  
 
Myelin Damage and Oligodendrogliosis in MPTP-induced Parkinsonism  
To date, it is unknown whether and with which progression axons of MPTP-affected 
neurons undergo degeneration and/or structural remodeling, which also involve 
modification in their myelin sheath, and whether oligodendrocytes take part in any of 
these events. In this result session, we will report evidences of myelin alteration and 
oligodendrogliosis after acute and chronic MPTP treatment in mice and monkeys, 
respectively. We decided to treat this topic separately from the other body of results as 
these findings highlight that early axonal damage and oligodendrogliosis may be an 
aspect as important as neglected in the pathogenesis of parkinsonism. 
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MPTP acute treatment induces axonal and myelin damage in the mouse striatum 
At the aim to identify possible ultrastructural axonal alterations induced by MPTP 
intoxication we performed a comparative electron microscopy analysis of the striatum 
of both control and MPTP-treated mice (Fig. 19). In control animals, axons displayed 
what we can describe as a normal morphology (19A-C). Myelinated striatal axons were 
numerous (Fig. 19A), characteristically heterogeneous in shape, size and thickness of 
their myelin sheaths and running intermixed with several unmyelinated fibers (Fig. 19B, 
C). Myelin sheaths were well preserved, with the typical high electron-density, 
surrounding concentrically the axonal cylinder with alternate regions of compact and 
loose myelin (Fig. 19C). Axoplasms occupied most of the intra-myelin space, in which 
spatially organized microtubules, neurofilaments, different types of vesicles and 
mitochondria were recognizable (Fig. 19C). 
Seventy-two hours after acute MPTP intoxication, striatal axons appeared less in 
number and more sparsely distributed compared to control (Fig. 19A’), with spaces 
between one another possibly occupied by glial cell processes (Fig. 19B’). High 
magnification showed a number of prominent alterations, i.e. numerous axons were 
surrounded by a dramatically destructured myelin sheath, containing large vacuoles in 
the periaxonal and intermyelinic space caused by a consistent splitting of the myelin 
lamellae (Fig. 19B’-C’). In the majority of cases, vacuoles bulged from one side of the 
broken myelin sheath, compressing the inner axon against the opposite side of the 
sheath (Fig. 19C’), which determined axonal atrophy and axoplasm disorganization. At 
points, myelin breakdown could also occur (Fig. 19C’), which could cause exit of the 
axoplasm to the interstitial space (Fig. 19C’). Two weeks after the last MPTP injection, 
striatal axons, at least the myelinated ones, appeared fewer and more loosely arranged 
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respect to the 72 hrs time point (Fig. 19A’’). This was accompanied by a reduction in 
the frequency and volume of the intra-myelin vacuoles (Fig. 19B’’-C’’), remarking the 
observation that severity and extension of vacuolizations were highest at early stages 
(72 hrs) after MPTP treatment. After 2 weeks, myelinated axons were enveloped by thin 
myelin sheaths. In the majority of cases they were organized in loose myelin lamellae, 
suggesting the formation of new myelin sheaths, or contained small residual vacuoles, 
possibly identifying sites of repair of previously damaged myelin coats (Fig. 19C”). 
Usually, the analysis at this time point did not reveal the presence of dystrophic axons. 
 
 
Fig. 19. Electron micrographs showing myelin ultrastructural alterations following acute MPTP-treatment in 
mice. (A-C) Control mice. A) In control mice striatum, myelinated axons are numerous and characterized by different 
calibres, shape and myelin thickness. B-C) Healthy unmyelinated (some of them indicated by a) and myelinated 
axons are intermixed, the latter being surrounded by the typical multilamellar structure, which alternate loose and 
compact regions. (A’-C’) Mouse striatum 72 hours after MPTP injection. A’) Early after MPTP treatment, 
myelinated axons in the striatum appear less than in control and are loosely arranged. B’-C’) A high degree of myelin 
vacuolization is observed. Vacuoles are mainly characterized by the splitting and breakdown of the myelin lamellae 
(*) in both the periaxonal and intermyelinic spaces. Vacuolated myelin sheaths often surround dystrophic axons (A*), 
which remained compressed against one side of the myelin coat. Myelin coat can break at points (arrows) 
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determining the exit of the inner axoplasm (arrowheads in C’). Boxed area in B’ is enlarged in C’. (A’’-C’’) Mouse 
striatum 2 weeks after MPTP injection. (A’’) Myelinated axons are reduced respect to those in the striatum of control 
and 72 hours MPTP treated mice. (B’’-C’’) Intra-myelin vacuoles persist (*), but much reduced in volume with 
respect to 72 hrs treated mice. Thin (arrow) and loosely arranged myelin sheaths, composed by only few myelin 
leaflets (white arrows), are commonly found. Scale bars: 5 µm (A-A’’), 1µm (B-B’’), 500 nm (C-C’’) 
 
Axonal damage induced by MPTP treatment in mice was associated with a transient 
oligodendrogliosis in both SNpc and striatum 
Since OLs are engaged in the production, maintenance and repair of myelin in the CNS, 
we performed a stereological study of their number and morphology. We, therefore, 
immunolocalized at the confocal microscope specific MRPs in the mouse striatum and 
SNpc, in order to establish whether myelin alterations observed in the striatal axons at 
the electron microscope, could be associated with changes in the OLs state (Fig. 20).  
After MPTP treatment, confocal analysis (Fig. 20A-C, SNpc; Fig. 20A’-C’, striatum), 
combined with stereological evaluation of the immunopositive cells, showed a 
significant increase, compared to control mice, in the number, average area and total 
area of the MRP+ cells in both SNpc (Fig. 20D-F) and striatum (Fig. 20D’-F’), which 
suggested OL activation. Active OLs were characterized by hypertrophic cell bodies, 
thickened proximal processes and elevated arborization of the distal processes (Fig. 
20A, A’ control; Fig. 20B, B’, 72 hrs MPTP). All these parameters corresponded to a 
remarkable enlargement in OL cell body size, as indicated by the significant increase in 
both average and total areas per photographic field occupied by immunopositive cells 
(Fig. 20E-F, SNpc; Fig. 20E’-F’, striatum). Two weeks after MPTP treatment, confocal 
(Fig. 20C, C’) and stereological (Fig. 20D-F; 20D’-F’) analyses showed a significant 
decrease, respect to the 72 hrs-MPTP experimental group, in the number and cell body 
size (average and total area per field) of OLs, in both SNpc (Fig. 20C; 20D-F) and 
striatum (Fig. 20C’; 20D’-F’). Moreover, all the values relative to this group were 
significantly lower compared with, or equal to, control, suggesting a reversion of the 
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process. The only difference was observed in the number of MRP+ cells in the SNpc, 
which remained significantly higher than in control mice. Both series of images confirm 
the MPTP induced striking changes in shape and size of OLs. All these changes 
inversely correlated with TH immunoreactivity in the dopaminergic pathway (Fig. 21 
A-F, for SNpc and Fig. 21 A’-F’, for striatum) which showed a significant decrease 72 
hrs after the last MPTP injection and a partial, but significant, recovery after 2 wks, in 
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both SNpc and striatum. 
Fig. 20. Transient oligodendrogliosis in the SNpc and striatum of MPTP treated mice. (A-C, A’-C’) Confocal 
analysis of MRP immunolabeling (red) in the SNpc and striatum of control (A, A’) and MPTP-treated mice (B, B’, 
72 hrs; C, C’, 2 wks). Seventy-two hours after MPTP injection (B,B’) a prominent oligodendrogliosis is observed 
when compared to control animal (A,A’), which is drastically reduced after 2 weeks (C,C’). Cell nuclei are 
counterstained in blue with DAPI. (D-F; D’-F’) Stereological analysis shows that OL cell number (D, SNpc and D’, 
striatum) and average cell body size (E, SNpc and E’ striatum) are significantly increased in 72 hrs MPTP-treated 
mice respect to control. A similar increase is observed in the total area per photographic filed occupied by MRP+ cells 
(F, SNpc, F’, striatum). All these values significantly decrease after 2 wks from MPTP treatment. n = 4-5 
animals/experimental group. Histograms are the mean ± s.e.m. of the examined parameters; *p ≤ 0.05, calculated by 
the one way ANOVA (Duncan’s test).  
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Fig. 21. In mice, the level of MPTP-induced oligodendrogliosis is inversely correlated to the loss of the 
dopaminergic neurons and fibers of the nigro-striatal pathway. MPTP treatment in mice induces a transient 
oligodendrocytosis, evaluated by counting the number of MRP+ cells (A, B, A’, B’), their average cell body size area 
(in m2) (C, D, C’, D’) and the total area occupied by OLs (E, F, E’, F’), which is inversely proportional to the levels 
of TH immunostaining observed in both SNpc and striatum. These refer to both the number of TH+ cell (A, C, E and 
A’, C’, E’) and optical density of the TH+ fibers (B, D, F and B’, C’, F’). Pearson correlation coefficient R2 and the 
correspondent p values are indicated in each correlation graph. n = 15-20. 
A persistent oligodendrogliosis was observed in the striatum of parkinsonian monkeys 
two years after receiving MPTP treatment 
On the basis of the results obtained in mice, we analyzed whether OLs activation could 
persist years after the last MPTP injection in a chronic model of parkinsonism. A 
confocal microscope and stereological analysis was carried out on sections of monkey 
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striatum (subdivided in caudate and putamen) immunolabeled for MBP (Fig. 22). 
Parkinsonian monkeys showed a striking and significant increase in the number of 
MBP+ cells in both caudate (Fig. 22A-B’, confocal images; Fig. 22C, cell count) and 
putamen (Fig. 22E-F’, confocal images; Fig. 22G, cell count) respect to control 
monkeys. OLs also showed an evident increase in their cell body size, as we observed in 
mice 72 hrs after the MPTP treatment. However, because of the strong increase in the 
extracellular MBP staining, we were technically unable to measure the area occupied by 
MBP+ cells, as discussed in the methods section. Notably, we found an inverse 
correlation between the number of OLs, quantified in the caudate and the putamen of 
each monkey, and both the number of surviving dopaminergic neurons in the SNpc 
(Fig. 22D, caudate; Fig. 22H, putamen) and their TH+ axon projections to both areas of 
the striatum (Fig. 22D’, caudate; Fig. 22H’, putamen). 
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Fig. 22. Persistent oligodendrogliosis in parkinsonian monkeys’ striatum. Representative pictures of confocal 
analysis are shown in (A-B’) for the caudate and in (E-F’) for the putamen. A striking increase, respect to control, in 
MBP immunolabeling (red) is still observed two years after MPTP treatment (B-B’, F-F’). Cell nuclei are 
counterstained in blue with DAPI. (C-D’ and G-H’) Stereological analysis conducted on the confocal images reveals 
a significant increase in the number of OLs in parkinsonian monkey caudate (C) and putamen (G) compared to 
control animals. (D, D’ and H, H’) The increase in MBP+ cells is inversely proportional to the number of TH+ 
neurons counted in the SNpc (D, caudate; H, putamen) and to the optical density associated with the TH 
immunolabeling of the dopaminergic axons projecting to both caudate (E’) and putamen (H’). Control group: n = 3 
monkeys; parkinsonian group: n = 5 monkeys. The histograms in D and I represent the mean ± s.e.m. of the BMP+ 
cell number; ***p ≤ 0.001, calculated by the student’s t test. The Pearson correlation coefficient R2 is indicated in 
each of the correlation graphs (D, D’, H, H’). 
DISCUSSION 
 
In recent years, many experimental evidences described the involvement of the two 
major extracellular proteolytic pathways in brain, the MMP and the PAs/plasmin 
system, in different neurodegenerative diseases (Akenami, 1999; Lorenzl S, 2002; 
Lorenzl S, 2003; Melchor, 2003; Lovrecic, 2008; Sokolowska, 2009; Rosenberg, 2009; 
Bonneh-Barkay and Wiley, 2009; Mille JP, 2010). These proteases play important roles 
in a number of processes, which require remodeling of the ECM. MMPs can degrade all 
ECM proteins and several other substrates, including growth factors, cell membrane 
receptors and adhesion molecules. Because of this versatility, MMPs are implicated in 
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pathological and physiological processes very different from one another, such as cell 
migration, apoptosis, angiogenesis and inflammation (Sternlicht and Werb, 2001; 
Dzwonek, 2004; Yong VW, 2005; Ethell and Ethell, 2007; Agrawal, 2008; Candelario-
Jalil, 2009). Although a role for MMPs has been widely accepted in several 
neuropatholgies, their involvement in PD is still poorly investigated and elusive. 
Similarly, involvement of the PAs/plasmin system in this pathology is still completely 
unexplored. Plasmin, generated by cleavage of plasminogen by means of either tPA and 
uPA, is a serine protease with a large number of substrates. As MMPs, the PAs/plasmin 
system is involved in numerous brain physiological and pathological processes and the 
two systems may also act in combination, being the activation of some of the MMPs 
even operated by plasmin (Teesalu, 2002; Yepes and Lawrence, 2004; Pang, 2004; 
Sheehan and Tsirka, 2005; Reijerkerk, 2008). Alltogether, these data prompted us to 
investigate the role that MMPs and the PAs/plasmin proteolytic system may play, 
singularly or in combination, in the pathogenesis and/or progression of parkinsonism. 
At this aim, we used two major PD animal models, i.e. mice and monkeys, acutely and 
chronically treated with MPTP, respectively. 
 
Acute and chronic MPTP intoxication resolves in two different parkinsonian 
syndromes: why it is important considering both of them 
Investigations on post mortem brain tissues of PD patients and MPTP chronically-
treated monkeys provide a fixed image of advanced stages of PD or parkinsonism, 
which does not allow to unravel early or dynamic neurodegenerative events. The MPTP 
rodent model of parkinsonism (Vernice & Przedborski, 2007) well overcome this limit, 
allowing a point-to-point analysis of the cellular and molecular processes associated 
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with the progressive degeneration of the nigro-striatal pathway. In this thesis, we have 
shown, by TH immunohistochemistry, that early after (1 d) MPTP injection both the 
number of DA neurons in the SN and the intensity of TH immunolabeling in the 
striatum decreases significantly respect to control. However, in both areas of the 
nigrostriatal pathway, a partial recovery of the immunolabeling is seen after two weeks, 
suggesting that a number of affected neurons in the SN does not degenerate, but recover 
at later stages, possibly regenerating their damaged axons and re-innervate the striatum 
to some extent. This hypothesis is based on the fact that a decrease in TH 
immunolabeling does not necessarily indicate a generalized loss of DA neurons. In fact, 
TH is the rate limiting enzyme of the catecholamine synthesis, and its level of 
expression is strictly related to neuronal activity. Therefore, MPTP induces neuronal 
intoxication, which can or cannot evolve in a death process, but that surely imply a 
reduction in neuronal activity. All these phenomena are flanked by a prominent and 
transient gliosis (micoglia and astroglia), which reaches its highest peak in coincidence 
with the depression of the nigro-striatal pathway, as it occurs in PD. What we observe in 
mice acutely intoxicated with MPTP, however, is extremely different from the 
irreversible death process that a chronic treatment provokes in both human (Langston, 
1999) and monkeys (Kolata, 1983; Langston, 1984). The same study reported in this 
thesis performed on brain sections of monkey sacrificed years after receiving MPTP, 
indicates that in primates the massive loss of dopaminergic neurons and fibers is 
progressive and it is always associated with a neuroinflammatory reaction. 
Therefore, when compared with parkinsonian monkeys, the MPTP mouse model 
lacks one of the principal features characterizing the PD, i.e. the perpetuation 
throughout years of both neuronal death (Jenner, 1998; Carvey, 2006) and gliosis 
(McGeer, 1988; Hurley, 2003; Barcia, 2004). To date, it is still unknown whether glial 
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cells are actively involved in the progression of the dopaminergic neuron death. Indeed, 
both a neuroprotective and a deleterious role have been proposed (Hirsch, 2003). The 
observation of an activated glia phenotype, which is maintained over several years after 
MPTP intoxication in monkeys, suggests that some re-activation mechanisms may 
operate. Several studies describe a persistent release of pro-inflammatory cytokines 
within the CNS and the blood stream as a crucial factor in the perpetuation of the 
inflammatory glial reaction (Barcia, 2005; Godoy, 2008; Reale, 2009; Scalzo, 2009). In 
contrast with primates, mice do not show such persistent increase in the levels of 
cytokines in the blood, which may be consistent with a transient glial activation. 
Actually, previous reports have shown that MPTP-treated mice merely show a transient 
increase in pro-inflammatory cytokines after 24 hrs-72 hrs (Hebert, 2003; Brochard, 
2009; Kurkowska-Jastrzebska, 2009; Luchtman, 2009), dates in which we detected the 
highest levels of gliosis. 
Discrepancies between MPTP-induced parkinsonism in primates and rodents 
might be due to species differences and/or differences in the MPTP intoxication 
protocol. However, we believe very useful comparing results obtained with the two 
different models of parkinsonism, as we do not exclude that uncovering the 
mechanisms, which determine the “self-limiting” character of the neuronal death and 
neuroinflammation in mice, may be the key for identifying some of the factors 
responsible for its progression in primates. 
 
Which are the extracellular proteases positively modulated in parkinsonism? 
In the first part of the study we screened for changes in mRNA and protein levels of 
components of the PAs/plasmin system and of some of the MMP family (MMP-2, 
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MMP-9 and MMP-3, which are the most expressed in brain) in MPTP-induced 
parkinsonian mice.   
 In the brain, plasminogen activators, and in particular tPA, are constitutively 
expressed by neurons in regions involved in learning and memory (hippocampus), 
emotional states (amigdala), motor learning (cerebellum) and autonomic and endocrine 
functions (hypothalamus). In all these regions, tPA is involved in the regulation of 
synaptic plasticity and neuronal activity, either trough activation of plasmin cascade 
(Sallés and Strickland, 2002; Madani, 2003; Melchor and Strickland, 2005) or by a 
direct modulatory effect on glutamatergic and dopaminergic pathways (Nicole, 2001; 
Matys and Strickland, 2003; Samson and Medcalf, 2006). It is, therefore, concivable 
that any insult, damage or toxin, leading to a massive neuronal death, could down-
regulate PAs and plasminogen expression and/or activity, as we observed in both SN 
and striatum of MPTP-treated mice. The significant increase in tPA mRNA levels 
observed only in the SN 1hr after MPTP injection, is not contradictory with the 
depression of all other components of this enzymatic pathway. In fact, tPA mRNA may 
be under translational control, i.e. once transcribed it is stabilized and stored in neurons, 
being its expression regulated by its binding to the cytoplasmic polyadenylation element 
binding (CPEB) protein, which leads to the tPA mRNA polyadenylation and a 
subsequent rapid increase in tPA protein synthesis (Shin, 2004). Therefore, we suppose 
that soon after MPTP treatment, tPA m-RNA transcription is increased in response to 
the toxin and that the transcripts are stored in the cytoplasm and not immediately 
translated. However, the progressive neuronal loss prevails on both tPA mRNA and 
protein, thus determining a global depression of the tPA/plasmin system.  
The analysis of both m-RNA and protein levels of MMP-2, MMP-3 and MMP-
9, indicates that the only protease strongly modulated and activated by MPTP treatment 
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is the MMP-9. In fact, MMP-9 expression, protein synthesis and enzymatic activation 
vary with a kinetics that overlaps the decrease in both number of TH+ neurons in the 
SNpc and loss of TH+ fibers in the striatum, as well as the prominent gliosis observed 
in both brain areas. This strongly suggests a crucial role for MMP-9 in both reaction of 
the nigro-striatal pathway to MPTP administration, which consists in an early dying-
back of part of the SNpc neurons followed by partial rescue of dopaminergic pathway at 
later dates, and the simultaneous glial activation.  
The specific up-regulation of MMP-9 following toxic insult is in accord with the 
literature, which reports MMP-9 as normally present in CNS, prevalently expressed by 
neurons at low levels and upregulated following injuries (Rosemberg, 2001; Lee, 2003; 
Jidday, 2005; Candelario-Jalil, 2009). MMP-2, the other gelatinase which share with 
MMP-9 similar substrates, is constitutively expressed in brain, mainly by glial cells 
(Del Zoppo, 2007), and its levels may increase in some types of diseases associated 
with inflammation, when it often concentrates in the cerebrospinal fluid (CSF) 
(Rosenberg, 2002). MMP-3, along with MMP-9, is one of the major inducible MMP 
during neuroinflammation (Gurney, 2006; Kim, 2007; McClain, 2009; Candelario-Jalil, 
2009; Cho, 2009; Moon, 2009; Yamada, 2010). Our findings relative to MMP-3, did not 
reveal changes in its m-RNA levels in parkinsonian mice respect to control. However, 
before speculating about this matter, some considerations are mandatory. First of all, 
our results are relative only to mRNA levels, which may not necessarily change in 
accord with the proteic ones. Second, results obtained by real time RT-PCR are 
remarkably variabile from on animal and the other within the same group and signal 
detection required a high number of cycles. Third, Western immunoblot analysis 
performed with different primary antibodies was unsuccesfull in giving convincing 
MMP-3 immunopositive bands. Altogether, these points suggest that low levels of 
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MMP-3 mRNA and protein are limiting for a reliable detection in our experimental 
system. In effect, studies by other groups, illustrating a role of MMP-3 in 
neurodegenerative and neuroinflammatory processes, have all been performed on either 
cell cultures, or animal models different than ours, by using other experimental 
paradigms of neuroinflammation (Kim, 2007; McClain, 2009).  
By immunohystochemistry we show that MMP-9 is mainly expressed by 
neurons along the entire nigro-striatal pathway of both control and MPTP-treated mice 
and monkeys. Although in both species the percentage of glial cells (microglia, 
astrocytes, OLs) expressing MMP-9 in control conditions is low, MPTP treatment 
determines its significant increase in both SNpc and striatum (Fig. 23). These results are 
in accord with numerous studies demostrating that, in the CNS, endothelial cells, 
astrocytes, neurons, and microglia synthetize both MMP-2 and MMP-9, although 
MMP-9 expression appears to depend on the experimental conditions and treatments 
(Yong, 2005; Yin, 2006; Del Zoppo, 2007; Liu, 2007; Rylski, 2008; Wilczynski, 2008; 
Frontczak-Baniewicz, 2009; Michaluk, 2009; Candelario-Jalil, 2009; Lehmann, 2009; 
Walker and Rosenberg, 2010). 
An interesting aspect emerging by our studies is that while in monkeys the 
increase in MMP-9 expression by neuronal and glial cells persists years after the toxic 
insult (Fig. 24), correlating with the progressive loss of TH immunoreactivity, in the 
mouse model of acutely-induced parkinsonism the increased expression of MMP-9 in 
glial cells is transient, reverting in the majority of cases to control levels after two 
weeks from MPTP treatment (Fig. 23). This data is in accord with the observed 
remission of gliosis and partial recovery of neurons and fibers expressing TH at later 
dates (2 weeks).  
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Fig. 23 A,B. Percentages of the different cell types expressing MMP-9 in the SNpc (A) and striatum (B) of 
control and MPTP-injected mice, evaluated by stereological quantification, at the confocal microscope, of 
MMP-9 immunopositive cells. MMP-9 is mainly expressed by neurons. The percentage of MMP-9 immunopositive 
neurons in both SNpc and striatum decreases significantly after MPTP treatment, whereas that of all types of MMP-
9+ glial cells increases. The increase is more prominent for oligodendrocytes (Ols) in the striatum. All percentages 
return to almost control level afet two weeks. *p ≤ 0.05, calculated by the one way ANOVA (Duncan’s test). 
SNpc ctrl 24 hrs 48 hrs 72 hrs 2 wks
Neuron 75,9 3,9 66,7 4 63,6 3,2 71,4 4,1 68,6 3
OLs 8,6 0,3 20,3 1,2* 26,3 1,3* 30,6 1,3* 12,6 1,1
Astrocytes 4,5 0,9 10,6 0,7* 6,8 0,4 7 0,8 6,6 1,6
Microglia 1,9 1,3 7,5 3,2* 10,4 3,4* 10,9 3,6* 3,1 1,6
Striatum ctrl 24 hrs 48 hrs 72 hrs 2 wks
Neuron 73,5 2,2 72,5 5,8 58,2 4,6* 60,5 4,2 69,9 3,2
OLs 4,2 0,4 7,9 0,4* 11,5 0,8* 10,4 0,7* 12,6 0,7*
Astrocytes 2,5 0,3 6,2 0,5* 8 0,9* 9,7 1* 5,6 0,6*
Microglia 0,8 0,2 4,1 0,8* 3,6 1,3* 3,4 0,4* 2,6 0,2*
Striatum ctrl MPTP
Neuron 56,2 0,6 37,6 0,4**
OLs 24,2 0,3 36,05 0,3***
Astrocytes 16,8 0,2 36,7 0,3*
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Fig. 24. Percentages of the different cell types expressing MMP-9 in the striatum of control (A) and 
parkinsonian monkeys (B) evaluated by stereological quantification at the confocal microscope of MMP-9 
immunopositive cells. MMP-9 is mainly expressed by neurons and oligodendrocytes (Ols), in both control and 
parkinsonian monkeys. In the MPTP-treated group, the percentage of neurons immunopositive for MMP-9 decreases 
to a 20%, while MMP-9+ Ols and astrocytes increase. *p≤0.05, **p≤0.01, ***p≤0.001 calculated by the student’s t 
test. 
 
Alltogether, the results obtained in both mice and monkeys suggest that MMP-9 
may exert functions tightly correlated with both glial cell reaction to MPTP intoxication 
and neuronal death. Therefore, here we propose a dual role of MMP-9 in 
experimentally-induced parkinsonism: one related to the early response of SNpc neuron 
to MPTP intoxication, implying loss of part of the dopaminergic neurons, 
neuroinflammation, oligodendrogliosis and dopaminergic neuron axon degeneration, 
and the other coincident with the possible recovery of survived neurons and the partial 
dopaminergic re-innervation of the striatum. 
 
The injury phase 
The adherence of cells to the ECM provides survival signals through mechanisms that 
include activation of cell surface receptors, as integrins. Integrins, especially the β1 
subtype, regulate the activation of the PI3K/Akt pathway through the interaction with 
the integrin-linked kinase (ILK), and their loss induces apoptotic cell death both in vitro 
and in vivo by disrupting survival signaling (Saito, 2003; Bouchard, 2007).Early after 
MPTP intoxication, the most significant consequence in the SNpc is the loss of large 
part of dopaminergic neurons.This occurs primarily by block of the mitochondrial 
respiration by this specific neurotoxin, but a concert of other mechanisms cannot be 
excluded, especially in association with the perpetuation of neuronal death years after 
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intoxication (i.e. in monkeys), when the toxic molecule is no longer present in the 
organism. Recently, several lines of evidence have demonstrated that active MMP-9 is 
responsible for the shedding of adhesion molecules from the cell surface, thus 
disrupting cell-cell and cell-ECM signaling. This may resolve in an apoptoic signaling 
within cells (Gary and Mattson, 2001; Tagaya, 2001; Lee, 2004; Gyung, 2009), or 
promote cell plasticity (Luo, 2005; Takács, 2010). In particular, Gyung and colleagues 
showed in vivo that β1 integrin is probably a direct target of MMP-9 and that its 
disruption is responsible for the apoptotic death of hippocampal cells after pilocarpine-
induced status epilepticus (Gyung, 2009). Moreover, experiments both in vitro and in 
vivo, demonstrated that a selective MMP-9 inhibitor prevents the loss of β1 integrin 
from the surface of hippocampal neurons and rescues from seizure-induced apoptotic 
cell death (Gyung, 2009). Based on the results obtained in our experimental models, we 
hypothesize that following the primary action of MPTP on the block of the 
mitochondrial electronic chain in the dopaminergic neurons of the SNpc, affected/dying 
neurons may release factors, among which MMP-9, which could stimulate neighboring 
glial cells by cleaving cell surface reptors, activating chemotactic factors and/or 
degrading ECM to favor cell migration toward the sites of injury. Moreover, MMP-9 
expression by glial cells themselves increases, possibly amplifying their amoebid 
migration. Increased MMP-9 release, may ultimately contribute to the dopaminergic 
neuronal loss by cleaving, for example, the β1 integrin and triggering an apoptotic 
pathway.  However, the ultimate mechanism by which MPTP induces dopaminergic 
neuron death is still unclear, as recent studies in primates failed to show activated 
caspase-3 or fluoro-jade positive dopaminergic neurons long after MPTP insult 
(Garrido-Gil, 2009). 
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In our experimental models, MMP-9 could also exert its action on the basal 
lamina and tight junction proteins (TJPs) of endothelial cells (ECs) and, therefore, 
cooperate to the opening of the blood-brain barrier (BBB), which allows peripheral 
immune-cells to enter the CNS (Rosenberg, 2007; Jin, 2010). As an example, after 
cerebral ischemia, MMP-9 activity is responsible for the second BBB opening, which 
generally occurs 24-48 hrs after the initial opening, exhacerbating blood vessels 
damage. As a matter of fact, treatment with specific MMP inhibitors or with MMP-
neutralizing antibodies decreases infart size and prevents BBB breakdown after focal 
ischemic stroke (Rosemberg, 1998; Amantea, 2007; Rosemberg, 2009). Moreover, in a 
MMP-9 knockout mouse model of focal ischaemic lesion, damage to the BBB and size 
of infarct area are decreased (Gasche, 2001). Physiologically, BBB opening is a 
protective mechanism during CNS infections, which allows peripheral immune-cells to 
enter the brain and to attack noxious microorganisms. However, when the cause of 
barrier brackdown is not an infectious agent, the inflammatory response contributes to 
tissue damage (Candelario-Jalil, 2009). Several studies on PD patients and animal 
models suggest a pathogenic linkage between BBB disruption and dopapminergic 
neuron death (Faucheu, 1999; Barcia, 2004; Kortekaas, 2005; Yasuda, 2007; Rite, 2007; 
Chen, 2008). That BBB undergoes alterations in PD and parkinsonism was also 
indirectly confirmed by the observation of infiltrating peripheral immune-cell in 
dopaminergic areas of both PD patients and parkinsonism animal models (McGeer, 
2003; McGeer and McGeer, 2008; Kurkowska-Jastrzebska, 2009; Brochard, 2009). 
Several line of evidence raise also the possibility that in inflammatory states MMP-9 
released by ECs may be important for the extravasation of peripheral blood monocytes 
and leukocytes, as the enzyme degrades collagen type IV and entactin, both of which 
are major components of the blood capillary basement membrane (Nguyen, 2005; 
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Kolaczkowska, 2006; Nguyen, 2006; Higashida, 2010). In addition, expression of 
MMP-9 by monocytes could be envisioned as part of the program of 
monocyte/macrophage differentiation after exposure to a variety of inflammatory 
stimuli (Zhang, 1998; Vos, 2000; Serra, 2010). Because these evidences, we consider 
that ECs, as well as peripheral blood monocytes/leukocytes, may represent the fraction 
of MMP-9+ cells that we defined as “others” and that in our co-immunolocalization 
studies were immunonegative for all the specific cell markers used.  
As already highlighted, in both MPTP-intoxicated mice and monkeys, microglia 
and astroglia undergo prominent activation. These results are in accord with several 
experimental evidences, in both SNpc and striatum of MPTP treated mice, showing that 
during inflammation microglia proliferates and gradually changes its morphology from 
small-sized, quiescent and ramified (resting state) to amoeboid (activated state) 
(Giulian, 1991; Kreutzberg, 1996; Stence, 2001; Hirsch and Hunot, 2009). Moreover, 
Barcia and colleagues previously demonstrated that microglia activation is still present 
several years after the interruption of MPTP treatment, in both SNpc and striatum of the 
same monkeys used in this study (Barcia, 2004; Barcia, 2010). In the brain of both 
parkinsonian mice and monkeys (Barcia, 2004; Barcia, 2010) a prominent and localized 
astroglia activation is appreciated. Astrogliosis can be easily evaluated by both increase 
in the number of GFAP+ cells and morphological changes, in which the star-shaped 
astrocytes, characteristic of control conditions, transform into reactive cells with large-
sized perikarya from which numerous thick processes emanate (Wilhelmsson, 2006; 
Anastasia, 2009; Hirsch and Hunot, 2009). Our results evidenced that in the mouse 
model both microglia and astroglia activation are transient, following a typical 
“inverted-U” trend: i.e. glial activation reaches a maximum by 48-72 hrs after MPTP 
acute injection and drastically reverts at the end of the observation time (2 weeks). 
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Interstingly, MMP-9 synthesis by microglia and astroglia is positively correlated to the 
kinetics of glial cell activation, increasing concomitantly to the onset of gliosis and 
decreasing at lated dates. Accordingly, in monkeys, where the chronic MPTP treatment 
induces a persistent glial activation, MMP-9 synthesis remains significantly higher than 
control. Altogether, these results suggest that MMP-9 is somehow related with the 
events promoting the switch of glial cells from an inactive to an activated state. As 
proposed earlier in the Discussion and shown in the drawing of Fig. 25, MMP-9 may be 
released at first by intoxicated dopaminergic neurons in the SNpc and by their axons in 
the striatum. This would, in turn, facilitate the arrival of glial cells to the affected areas, 
a process that itself may benefit from prodution and site-specific release of MMP-9 by 
glial cells (see below). 
 
Fig. 25. Prosposed role of MMP-9 in glial cell activation after MPTP intoxication. MMP-9, sinthetised mainly by 
neurons, contributes to glia activation. In turn, MMP-9 released by activated glial cells, along with other factors, may 
trigger a reverberating inflammatory process, which ultimately increases loss of DA neuron. 
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A survey of the literature on rodents suggests that microglial cells and/or 
astrocytes may provide a source of MMP-9 when stimulated by pro-inflammatory 
cytokines (Rivera, The MIT press pag. 53-86; Yong, 2005; Ben Hur, 2006; del Zoppo, 
2007). Recently, in vitro studies have demonstrated that microglia and astroglia 
stimulated with α-synuclein release MMP-9, concomitantly to changes in their 
morphology (So, 2010; Lee, 2010). MMP-9 secreted by the stimulated microglia, in 
turn, activates microglia itself by activating the protease-activated receptor-1 (PAR-1) 
in an autocrine and/or paracrine manner (Lee, 2010). PARs are G protein-coupled 
receptors that signal in response to extracellular proteases. After the N-terminal 
extracellular domain of PAR-1 has been digested by proteases, the remaining domain 
acts as tethered ligand and generates intracellular signals (Vu, 1991). PAR-1 has been 
demonstrated to be located on the surface of microglial cells and the binding of PAR-1 
to its ligand activates microglia (Suo, 2002). Lee and colleagues have also demonstrated 
that MMP-9 cleaves PAR-1 with a high efficacy and that blocking MMP-9 activity 
significantly suppresses the expression of iNOS, TNF-α, IL-1β and ROS production by 
microglia, producing an effect similar to that exherted by the PAR-1 specific inhibitor 
(Lee, 2010). These results indicate a role for MMP-9 in the perpetuation of microglia 
activation. The same authors also reported that inhibition of MMP-9 suppresses 
microglia activation by LPS in vitro (Woo, 2008), suggesting that the enzyme may 
indeed play a role as a mediator of inflammation and that PAR-1 is part of a 
mechanisms of MMP-mediated microglial activation.  
It’s well-known that in response to brain injury, both microglia and astroglia 
migrate and accumulate at the sites of damage, which represent an important step in the 
regulation of inflammation and neuronal degeneration/regeneration. Supported by 
numerous evidences (Machida, 1989; del Zoppo, 2007; Choi, 2010; Shin, 2010; Sbai, 
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2010), we believe that the increase in MMP-9 synthesis associated to glia activation 
after MPTP administration may mediate also migration of glial cells promoting 
advancement of lamellipodia, protusion of invadopodia, as well as regulation of 
chemotactic signals. Recent reports suggest that ATP, released by apoptotic cells, may 
also acts as chemotactic signal to recruit fagocytic cells into damaged areas, 
highlighting a crucial role of ATP via MMP-9 secretion in the regulation of an 
inflammatory phenotype in brain injury (Elliot, 2009; Choi, 2010). Sbai and colleagues 
demonstrated that MMP-9 and MMP-2 have a different intracellular vesicular 
distribution in LPS-activated astrocytes.  Specifically, MMP-9, but not MMP-2, was 
localized in vesicles positive for the lysosomal-associated membrane protein-2 (LAMP-
2) (Sbai, 2010). Moreover, time-lapse live-cell imaging revealed that these MMP-9+ 
lysosomal vesicles move to, and fuse with, the plasma membrane at the podosomes of 
activated astrocytes. Because it has been demonstrated that these structures mediate cell 
migration and invasion by coordinating the reorganization of cytoscheleton and by focal 
degradation of the ECM via MMPs and/or serine proteases (Tu, 2008), the above 
mentioned results indicate that MMP-9 gelatinolytic activity is involved in the 
regulation of reactive astrocytes migration. 
Our results show that in parkinsonian primate, microglia and astroglia activation 
persists in association with both their MMP-9 production and progressive neuronal 
death years after the initial toxic insult. We, therefore, hypothesize that in this animal 
model, differently from mice, pathophysiological mechanisms, involving MMP-9 and 
directed to maintain the inflammatory state, were not correctly modulated. In this case, 
the persistence of gliosis may become detrimental due to persistent release of potentially 
neurotoxic factors (i.e. ROS, cytokines) and by formation of an impenetrable glial scar, 
which would block any attempt of damaged axon re-growth, possibly triggering the 
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progression of neuronal death (Yong, 2005; Williams, 2007; Franklin and ffrench-
Constant, 2008; Moore, 2010).  
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The repair phase 
Our results demonstrate that acute MPTP intoxication in experimental parkinsonism in 
mice induces a prominent oligodendrogliosis within 72 hrs from toxin administration, 
which parallels the loss of 50-60% of the dopaminergic neurons in the SNpc and of their 
axons projecting to the striatum. This phenomenon, well characterized by confocal and 
stereological analysis, reflects different degrees of myelin sheath damage, clearly 
identified at the electron microscope, which range from intramyelinic oedema and 
swelling, to disruption of the myelin coat with consequent axonal atrophy and axoplasm 
extrusion, in the most severe cases. These myelin alterations associated to massive 
oligodendrogliosis along the entire dopaminergic pathway are exacerbated in the 
striatum. This may be related to the fact that MPP+, the toxic product of MPTP 
metabolism in glial cells (Di Monte, 1992) is captured by dopaminergic axon terminals, 
where mitochondrial intoxication begins, and then are retrogradely transported to the 
cell body, progressively affecting the entire neuron. This peculiar mechanism of 
retrograde action is shared by other pathological situations consequent to the 
administration of different neurotoxins (Horton, 2009; Cliffer, 1998). Altogether, the 
evidences here presented support that dysfunction of dopaminergic axons and synapses 
in parkinsonism precedes that of dopaminergic neuron cell bodies and that probably the 
surviving dopaminergic neurons, with damaged axons, cannot properly function. In 
human PD, dopaminergic axons are severely affected (i.e. varicosities, disruption and 
shrinkage) (Duda, 2003; Kieburtz, 2007) and several authors have hypothesized that 
axonal degeneration may indeed precede neuronal apoptosis and protein aggregation 
(i.e. alpha-synuclein) in nerve fibers (Lewy neurites), suggesting that axon degeneration 
may be one of the initial causes of neuronal loss (Braak, 1999; Duda, 2002). However, 
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this may be something specific for humans, since no lewy pathology is observed in 
chronic parkinsonian monkeys (Halliday, 2009). One of the most intriguing aspects of 
our study, which may sustain this hypothesis, is that in mice, 2 wks after acute MPTP 
administration, we observed a partial recovery of TH immunoreactivity in both SNpc 
and striatum, concomitant to a reduction in the oligodendrogliosis and a partial rescue 
of the integrity of the myelin sheaths wrapping the remaining axons. This opens an 
important aspect concerning OL activation, which is their involvement in the initiation 
of a remyelinating process in the survived dopaminergic neurons (Levine, Reynolds, 
1999; Reynolds, 2002; Franklin, 2008; Kitamura, 2010). Because an early step in fiber 
regeneration/remyelination is the production of extensive processes by oligodendrocytes 
to contact several axons, a requirement for MMP activity in remodelling the ECM 
seems likely (Hughes, 2002). In particular, MMP-9 could exert a crucial role, because 
its expression was often associated with OL activation in regenerative processes in CNS 
(Uhm, 1998; Larsen, 2003; Larsen, 2006). This hypothesis is improved by our results 
obtained in mice, which show as in the nigro-striatal pathway the MPTP-induced 
oligodendrogliosis is associated to an early and gradual increase in MMP-9 expression 
by OLs, which is significantly reverted 2 wks after the treatment, when OLs lose their 
activated state (Fig. 26).  
CTRL 72 hrs after MPTP 2 wks after MPTP
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Fig. 26. MPTP acute PD model in mice. In control mice, neurons of SNpc project their axons to the striatum 
establishing the necessary connections for correct neural transmission. In the absence of damages, no evidences in 
glial activation are observed along the nigro-strial dopaminergic pathway. Following MPTP acute treatment, 
microglia and astrocytes, as well as oligodendrocytes, become activated. It is well known that MPTP induces a dying-
back axonal damage in the striatum. In this scenario, the MMP-9 expression increases in both neurons and glial cells 
of both SNpc and striatum. The MMP-9 enzymatic activity may be crucial for the remodeling of the ECM and 
triggers oligodedrogliosis. We hypothesize that in the mouse model, in a final phase (2 wks), oligodendrocytes may 
contribute to a partial rescue of the affected dopaminergic neurons by favoring axonal re-growth, a processes in 
which MMP-9 could also have a role.  
 
At this regard, Yong and colleagues described that OLs express MMP-9 to 
extend processes along an astrocyte ECM in vitro (Uhm, 1998). For tissue culture 
studies, OLs cultured from adult human or mouse brains are stripped of their processes 
during the cell isolation process, and the re-growth of processes provides a model of 
potential remyelinating capacity. The authors found that process re-extension by adult 
murine OLs is impaired in cells derived from MMP-9-null mice compared with the 
wild-type and that inhibitors of MMP-9 reduce cell process extension (Oh, 1999). These 
in vitro experiments were extended to models of remyelination in adult mice, in which a 
demyelinating insult was produced in the spinal cord by the lipid disrupting agent 
lysolecithin. The authors showed that after demyelization in adult mice the subsequent 
remyelination in MMP-9-null mice was retarded compared with that in tha wild-type 
animals (Larsen, 2003). The proposed role of MMP-9 in remyelination in vivo was 
attributed in part to the cleavage of NG2, a chondroitin sulfate proteoglican (CSPG) 
deposited into the ECM following injury, by MMP-9. In the absence of MMP-9, NG2 
remains within the ECM and provids an inhibitory barrier that prevents the maturation 
of OLs into myelin forming cells (Larsen, 2003). On the other hand, MMP-9 is also 
implicated in the digestion of MBP, promoting demyelination in PNS (Chattopadhyay, 
2007; Kobayashi, 2008). This activity could also be important for astrocytes, microglia 
and macrophages in order to remove myelin debris (Fancy, 2010; Franklin and Kotter, 
2008; Nielsen, 2009). Pathological studies have revealed that chronically demyelinating 
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lesions in MS often fail to repair because of a failure in the differentiation of precursor 
cells responsible for remyelination, rather than a failure in their recruitment (Franklin 
and Kotter, 2008), as molecules accumulated in the myelin debris can inhibit OL 
differentiation (Hughes, 2002; Liu, 2008; Fancy, 2010).  
Considering this scenario, in our mouse PD model, MMP-9 could take part in 
two series of events, as is summarized in the diagram of Fig. 27. First, early after the 
injury, it may favor axonal retration by damaged neurons, disassembling their myelin 
sheaths by digestion of MBP and/or of other proteins important for myelin stabilization, 
as dystroglycan (Chattopadhyay, 2007; Kobayashi, 2008; Shiryaev, 2009; Zhao, 2010). 
This in turn may induce a “dying-back” degeneration of neurons. In a second series of 
events, MMP-9 may support new terminal axon sprouting in those dopaminergic 
neurons which survived MPTP intoxication, promoting ECM remodeling and debris 
scavenging by appropriated cells (Webber, 2002; Larsen, 2003; Saxena and Caroni, 
2007; Murray, 2008). All these processes will ultimately bring to a partial reinnervation 
of the striatum, as suggested by the recovery of TH immunolabeling in both SNpc and 
striatum, as well as the ultrastructural analysis conducted at the electron microscope. 
Also the observation that after a critical period of abut 72 hrs, mice apparently recover 
their motor skills, conforts this hypotheis. 
 
MMP-9
MMP-9
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Fig. 27. MMP-9 regulates myelin. In response to a nocive stimulus MMP-9 could be involved in both myelin 
disruption and reparing. Early after injury, the increase in MMP-9 levels may have a significant role in the 
fragmentation of MBP, or of other proteins important for myelin stabilization, triggering the disorganization of the 
myelin sheets around axons and favouring its retraction. On the other hand, following demyelination, in the adult 
mouse SNC, MMP9 regulates remyelination. One mechanism through which this could be achieved is the clearance 
of proteoglycans, which constitute an inhibitory barrier for oligodendrocytes maturation and their subsequent 
reformation of myelin. The enzyme can also remove from sites of CNS injury some oligodendrocyte myelin 
glycoproteins and ECM proteogycans, which inhibit the new axonal growth. 
 
The results we obtained in the monkey model of chronic MPTP administration 
differ, but do not contradict, those described in the mouse model. Two years after the 
establishment of stable parkinsonism, in the monkey striatum, both number and size of 
OLs are still higher than control, being the oligodendrogliosis more prominent in those 
monkeys with a more severe dopaminergic depletion. As shown the diagram in Fig. 28, 
OL activation and their MMP-9 synthesis is perpetuated along the years and, differently 
from mice, there is no partial rescue of the nigro-striatal dopaminergic system.  
 
Fig. 28. MPTP chronic PD model in non-human primates. The diagram represents the alterations observed in the 
striatum of parkinsonian primates, years after the interruption of MPTP treatment. Features of oligodendrogliosis and 
both astroglia and microglia activation are still present, concomitant with the persistance of MMP-9 protein levels 
higher than controls. In the MPTP chronic PD the absence of a phase of gliosis regression and DA system recovery, 
observed in mice, suggests that the perpetuation of the neuroinflammatory processes may sustain the characteristic 
progression of the parkinsonian syndrome.  
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Therefore, we hypothesize that, in the chronic model of experimental 
parkinsonism, the initial neuronal damage may activate oligodendrogliosis and a 
cascade of glia-mediated inflammatory signals able to perpetuate themselves and 
probably induce progressive neuronal loss (Czlonkowska, 2001; Brochard, 2009; Saijo, 
2009). In this situation, the persistence of an inflammatory stimulus years after MPTP 
injections (Barcia, 2004; McGeer, 2003), may promote the formation of a glial scar at 
sites of axon degeneration, imposing a barrier to a possible regeneration (Smith-
Thomas, 1994; Fidler, 1999; Silver and Miller, 2004; Rolls, 2009) and creating a hostile 
environment in which OL activity may become ineffective compared with acute lesions 
(Foote and Blakemore, 2005; Setzu, 2006; Goldschmidt, 2009). In this context, the 
persistent expression of MMP-9 could be advocated to the high number of 
inflammatory cells, present at the injury sites. The chronic inflammation observed in 
monkeys respect to the transient inflammatory state characteristic of parkinsonian mice 
entails a series of differences in gene expression by the different cell types involved in 
the process, which might determine whether MMP-9 has a beneficial or detrimental 
function in this PD models. Probably, in primate parkinsonism, lack of mechanisms able 
to regulate a discreet and local MMP-9 expression, may affect both remodelling and 
repair processes after the initial phase of the injury, as it occurs in mice.  
Our studies emphasize that myelin degeneration may play an important role in 
parkinsonism, but its function and mechanisms in the human disease needs to be further 
investigated. Very little has been reported on the involvement of OLs in PD. Previous 
investigations have shown the presence of complement-activated OLs in the SNpc in 
only a few cases of PD (Yamada, 1991). However, its relation with the disease remains 
unclear and it has been largely overlooked by researchers (McGeer and McGeer, 2008). 
In this innovative aspect, the possible role of MMP-9 needs to be further investigated in 
126 
 
order to open a window on new specific therapeutic strategies aimed at preventing, or 
minimize, axonal degeneration.  
 
Conclusion and future directions 
In this thesis we demonstrated in vivo an upregulation of the MMP-9 in MPTP-induced 
parkinsonism in mice and monkeys. However, how does MMP-9 achieve it effects and 
what are its specific roles are awiting further elucidation. Indeed, our data give us a 
precious background on which speculating a series of functions in different moments of 
the nigro-striatal pathway response to MPTP intoxication and of the development of a 
neuroinflammatory response. More indicative results are expected from the use of mice 
knock-out for MMP-9 activity (Wang, 2000; Asahi, 2001). MMP9-null mice and their 
corresponding wild-type mice have already been treated with MPTP in order to observe, 
by immunohistochemistry for the different neuronal and glial cell-specific markers, 
already utilized throughout this work of thesis, whether the absence of this enzymatic 
activity attenuates, or exacerbates, the dopaminergic neuron death and/or the 
neuroinflammatory response to the toxic insult. Clarify this point will be also useful for 
the interpretation of the results obtained in monkeys. In fact, post-mortem analysis of 
parkinsonian monkeys provide a final picture of this neuropathology, which could just 
suggest that glial activation, neuronal loss and increased MMP-9 expression are 
connected, but without giving hints on the original cause of the entire process. 
Conversely, the mouse model give us a dynamic experimental system, in which after a 
critical stage (48-72 hrs) a partial rescue of the nigro-striatal dopaminergic pathway is 
observed. Once clarified all the unresolved queries in mice, we will able to focus our 
research on parkinsonian monkeys, hoping to shed a light on a possible role for MMP-9 
in human PD. 
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